

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2021 OF THE CONDITION AND AFFAIRS OF THE

Arcadian Health Plan, Inc.

| NAIC | | | / Code <u>12151</u> Employer's I | D Number <u>20-1001348</u> |
|--|---|---|--|---|
| Organized under the Laws of | , | (Prior) ington | , State of Domicile or Port of E | ntry WA |
| Country of Domicile | | United St | tates of America | |
| Licensed as business type: | | | Other | |
| Is HMO Federally Qualified? | Yes[]No[X] | | | |
| Incorporated/Organized | 04/06/2004 | | Commenced Business _ | 01/01/2005 |
| Statutory Home Office | 300 Deschutes Way (Street and N | | , (City o | Tumwater, WA, US 98501 r Town, State, Country and Zip Code) |
| Main Administrative Office | | | est Main Street | |
| | Louisville, KY, US 40202 | | | 502-580-1000 |
| (City or | Town, State, Country and Zip (| Code) | () | Area Code) (Telephone Number) |
| Mail Address | P.O. Box 740036 (Street and Number or P | | | Louisville, KY, US 40201-7436 r Town, State, Country and Zip Code) |
| Primary Location of Books and | , | , | est Main Street | , , |
| ,, | | | and Number) | 502-580-1000 |
| (City or | Louisville, KY, US 40202 Town, State, Country and Zip (| Code) | | Area Code) (Telephone Number) |
| Internet Website Address | | www. | humana.com | |
| Statutory Statement Contact | Aman | da Nethery | , | 502-580-1624 |
| [| OOIINQUIRIES@humana.com | (Name) | | (Area Code) (Telephone Number) 502-580-2099 |
| | (E-mail Address) | | | (FAX Number) |
| | | | FICERS | |
| President _ Associate VP, Asst Gen | Bruce Dale E | roussard | Chief Financial Officer _ | Elizabeth Lisa Ferrari |
| Counsel & Corporate Secretary _ | Joseph Matthe | w Ruschell | SVP, Chief Actuary _ | Vanessa Marie Olson |
| | | C | OTHER | |
| Alan James Baile | ey, VP & Treasurer | | vin, Chief Executive Officer | Susan Marie Diamond #, Executive Vice President- Finance |
| Courtney Danielle Durall, A | ssistant Corporate Secretary | Jeremy Leon Gaskill # | , VP, Employer Group Regional President | Steven Edward McCulley, SVP, Medicare |
| | re. Regional President | Sean Joseph O'Reilly, | SVP, Enterprise Compliance & compliance Officer | William Mark Preston, VP, Investments |
| George Renaudin II, SVP, M | Medicare Markets, Economics Experience | | Robinson, SVP, Tax | Susan Draney Schick #, Segment President, Group & Military Business |
| | Medicare Divisional Leader | Michael Poul Tilton #, | VP, Employer Group Regional President | Daniel Andrew Tufto, SVP, Medicare Divisional Leader |
| Richard Andrew Vollmer J | r., SVP, Medicare Divisional | Timothy Alan Wheatl | ey, Segment President, Retail | Ralph Martin Wilson, Vice President |
| | le, SVP, Chief Accounting Controller | | | |
| | | DIRECTOR | S OR TRUSTEES | |
| Ricky How | vard Beavin | | Dale Broussard | Joseph Matthew Ruschell # |
| State of | Kentucky | | | |
| County of | Jefferson | SS | | |
| all of the herein described as statement, together with relate condition and affairs of the sai in accordance with the NAIC rules or regulations require respectively. Furthermore, the | sets were the absolute propert ad exhibits, schedules and explaid d reporting entity as of the repo- Annual Statement Instructions differences in reporting not re- e scope of this attestation by the | y of the said reporting e anations therein containe orting period stated above and Accounting Practice: lated to accounting pra he described officers also | ntity, free and clear from any lien- d, annexed or referred to, is a full a , and of its income and deductions s and Procedures manual except ctices and procedures, according o includes the related corresponding | porting entity, and that on the reporting period stated above sor claims thereon, except as herein stated, and that thi and true statement of all the assets and liabilities and of the stherefrom for the period ended, and have been complete to the extent that: (1) state law may differ; or, (2) that state to the best of their information, knowledge and belief to the best of their information, whom required, that is any be requested by various regulators in lieu of or in addition |
| Bue Bro | unal | | worh()) | alang. Bailey |
| Bruce Dale Bro Presiden | | Assoc. VP, Asst. Ge | latthew Ruschell eneral Counsel & Corporate Secretary | Alan James Bailey VP & Treasurer |
| Subscribed and sworn to befo 21st day of Julia Wentworth Hotary Public | Febru: | ary, 2022 | a. Is this an original filin b. If no, 1. State the amendm 2. Date filed | nent number |
| January 10, 2025 | Julia Went | worth | | |

Julia Wentworth Notary Public State at Large Kentucky

ASSETS

| | | | Current Year | | Prior Year |
|------------|--|----------------|-------------------------|---|-----------------------------|
| | | 1 Assets | 2 Nonadmitted Assets | 3 Net Admitted Assets (Cols. 1 - 2) | 4 Net Admitted Assets |
| 1. | Bonds (Schedule D) | | | 1,258,696,958 | |
| 2. | Stocks (Schedule D): | | | | , , |
| | 2.1 Preferred stocks | 0 | 0 | 0 | 0 |
| | 2.2 Common stocks | | | 1 | 0 |
| 3. | Mortgage loans on real estate (Schedule B): | | | | |
| | 3.1 First liens | 0 | 0 | 0 | 0 |
| | 3.2 Other than first liens | | | 1 | 0 |
| 4. | Real estate (Schedule A): | | | | |
| | 4.1 Properties occupied by the company (less \$ | 0 | 0 | 0 | 0 |
| | 4.2 Properties held for the production of income (less \$ | | | 0 | 0 |
| | 4.3 Properties held for sale (less \$0 encumbrances) | | | | 0 |
| 5. | Cash (\$ | | | | |
| _ | | | | 1 | |
| | Contract loans, (including \$ | | | I I | |
| 7. o | | | | | |
| 8. | Other invested assets (Schedule BA) Receivables for securities | | | 1 | |
| 9. | Securities lending reinvested collateral assets (Schedule DL) | | | | 5,000 |
| 10. | Aggregate write-ins for invested assets (Schedule DL) | | | | |
| 11. | Aggregate write-ins for invested assets Subtotals, cash and invested assets (Lines 1 to 11) | | | | |
| 12. | · | 1,403,619,037 | | 1,403,619,037 | 1,345,071,219 |
| 13. | Title plants less \$ | 0 | 0 | | 0 |
| 14 | Investment income due and accrued | | | 6,261,686 | |
| 14. | | 0,201,000 | | 0,201,000 | |
| 15. | Premiums and considerations: 15.1 Uncollected premiums and agents' balances in the course of collection. | 700 575 | 782 307 | 17 268 | 500 660 |
| | | 199,373 | 102,307 | 17,200 | |
| | 15.2 Deferred premiums and agents' balances and installments booked but | | | | |
| | deferred and not yet due (including \$0 earned but unbilled premiums) | 0 | 0 | _ | 0 |
| | 15.3 Accrued retrospective premiums (\$12,163,847) and | 0 | | | |
| | contracts subject to redetermination (\$ 123.741.236) | 135.905.084 | 0 | 135.905.084 | 114.076.212 |
| 16 | γ | | | 130,303,004 | 114,070,212 |
| 16. | Reinsurance: 16.1 Amounts recoverable from reinsurers | 0 | 0 | 0 | 0 |
| | 16.2 Funds held by or deposited with reinsured companies | | | 1 | 0 |
| | 16.3 Other amounts receivable under reinsurance contracts | | | | 0 |
| 17. | Amounts receivable relating to uninsured plans | | | | 33,442,902 |
| | | | | | 0 |
| | Net deferred tax asset | | 736,479 | | 10,304,552 |
| 19. | Guaranty funds receivable or on deposit | | | 0 | 0,304,332 |
| 20. | Electronic data processing equipment and software | | | 1 | |
| 21. | Furniture and equipment, including health care delivery assets | 0 | | | 0 |
| 21. | (\$ | 0 | 0 | 0 | 0 |
| 22. | Net adjustment in assets and liabilities due to foreign exchange rates | | | 1 | 0 |
| 23. | Receivables from parent, subsidiaries and affiliates | n | 0 | | 0 |
| 23. 24. | Health care (\$130,701,758) and other amounts receivable | | 37,608,516 | | 87,782,760 |
| 25. | Aggregate write-ins for other than invested assets | | | | 07,702,700 |
| 26. | Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25) | | | 1,751,171,135 | |
| 27. | From Separate Accounts, Segregated Accounts and Protected Cell Accounts | | | 0 | 0 |
| 28. | Total (Lines 26 and 27) | 1,824,365,753 | 73, 194, 618 | 1,751,171,135 | 1,596,487,759 |
| | DETAILS OF WRITE-INS | | | | |
| 1101. | | 0 | 0 | 0 | 0 |
| 1102. | | | | | |
| 1103. | | | | | |
| 1198. | Summary of remaining write-ins for Line 11 from overflow page | 0 | 0 | 0 | 0 |
| 1199. | Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above) | 0 | 0 | 0 | 0 |
| 2501. | Prepaid Expenses | 18 , 177 , 529 | 18,177,529 | 0 | 0 |
| 2502. | Prepaid Commissions | 8,665,904 | 8,665,904 | 0 | 0 |
| 2503. | Provider Contracts | 7,223,882 | 7,223,882 | | 0 |
| 2598. | Summary of remaining write-ins for Line 25 from overflow page | 0 | 0 | 0 | 0 |
| 2599. | Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above) | 34,067,316 | 34,067,316 | 0 | 0 |

LIABILITIES, CAPITAL AND SURPLUS

| | LIADILITIES, CAF | | | 1 | Deice Vers |
|----------|---|-------------|-------------------|----------------|-----------------|
| | - | 1 | Current Year 2 | 3 | Prior Year 4 |
| | | ' | - | | • |
| | | Covered | Uncovered | Total | Total |
| 1. C | claims unpaid (less \$0 reinsurance ceded) | 610,953,475 | 33,387,085 | 644,340,560 | 568, 187, 547 |
| 2. A | ccrued medical incentive pool and bonus amounts | 75,125,513 | 0 | 75,125,513 | 91,212,103 |
| 3. U | Inpaid claims adjustment expenses | 4.076.766 | 0 | 4,076,766 | 3.965.487 |
| | ggregate health policy reserves, including the liability of | , , | | , , | , |
| 7. / | \$0 for medical loss ratio rebate per the Public | | | | |
| | | 07 000 057 | | 07 000 057 | 10 007 117 |
| | Health Service Act | | | | |
| | ggregate life policy reserves | | | 0 | |
| 6. P | roperty/casualty unearned premium reserves | | 0 | 0 | 0 |
| 7. A | ggregate health claim reserves | 0 | 0 | 0 | 0 |
| | remiums received in advance | | | 4.893.314 | 3.622.565 |
| | eneral expenses due or accrued. | | | I . | |
| | • | 0,770,240 | | 0,770,240 | 7 , 400 , 007 |
| | current federal and foreign income tax payable and interest thereon | 0.050.577 | | 0.050.537 | F 470 007 |
| | including \$235,440 on realized capital gains (losses)) | | | | |
| | et deferred tax liability | i | | 0 | |
| 11. C | eded reinsurance premiums payable | | 0 | 0 | 0 |
| 12. A | mounts withheld or retained for the account of others | 341 | 0 | 341 | 378 |
| 13. R | lemittances and items not allocated. | 2.204.560 | 0 | 2.204.560 | 1.085.310 |
| | orrowed money (including \$0 current) and | , , | | | , , |
| | nterest thereon \$0 (including | | | | |
| | | | | | • |
| | \$0 current) | i i | | l l | |
| | mounts due to parent, subsidiaries and affiliates | ' ' | | 30 , 026 , 184 | 15,412,094 |
| 16. D | erivatives | 0 | 0 | 0 | 0 |
| 17. P | ayable for securities. | 299 | 0 | 299 | 2,789,563 |
| | ayable for securities lending | | | 0 | 0 |
| | unds held under reinsurance treaties (with \$0 | | | | |
| | , | | | | |
| | authorized reinsurers, \$0 unauthorized | | | | |
| 1 | reinsurers and \$0 certified reinsurers) | 0 | 0 | 0 | 0 |
| 20. R | einsurance in unauthorized and certified (\$ | | | | |
| (| companies | 0 | 0 | 0 | 0 |
| 21. N | let adjustments in assets and liabilities due to foreign exchange rates | 0 | 0 | 0 | 0 |
| | iability for amounts held under uninsured plans | 37.553.728 | | 37,553,728 | 5.871.837 |
| | ggregate write-ins for other liabilities (including \$ | | | | |
| , | current) | 407 200 | | 407 200 | 201 705 |
| | | | | | |
| | otal liabilities (Lines 1 to 23) | | | I . | |
| | ggregate write-ins for special surplus funds | | | | |
| 26. C | ommon capital stock | XXX | XXX | 1,000,020 | 1,000,020 |
| 27. P | referred capital stock | xxx | xxx | 0 | 0 |
| 28. G | Gross paid in and contributed surplus. | XXX | XXX | 624.630.733 | 624.630.733 |
| | urplus notes. | | | l l | |
| | · | | i | | |
| | ggregate write-ins for other than special surplus funds | | | I | |
| | nassigned funds (surplus) | XXX | XXX | 287,292,654 | 253,414,4/6 |
| 32. L | ess treasury stock, at cost: | | | | |
| 32 | 2.10 shares common (value included in Line 26 | | | | |
| | \$ | XXX | xxx | 0 | 0 |
| 3. | 2.2 | | | | |
| 3, | | VVV | VVV | | ^ |
| | \$ | | | I . | |
| 33. T | otal capital and surplus (Lines 25 to 31 minus Line 32) | XXX | XXX | 912,923,407 | 8/9,045,229 |
| 34. T | otal liabilities, capital and surplus (Lines 24 and 33) | XXX | XXX | 1,751,171,135 | 1,596,487,759 |
| D | ETAILS OF WRITE-INS | | | | |
| 2301. Ui | nclaimed Property | 497.380 | 0 | 497,380 | 391.795 |
| | 1. 7 | | | | |
| | | | | | |
| | | | | i | |
| | ummary of remaining write-ins for Line 23 from overflow page | | | 0 | |
| | otals (Lines 2301 thru 2303 plus 2398)(Line 23 above) | 497,380 | 0 | 497,380 | 391,795 |
| 2501 | | xxx | xxx | 0 | 0 |
| | | | | | |
| | | | | | |
| | | | | | |
| | ummary of remaining write-ins for Line 25 from overflow page | | | l l | |
| | otals (Lines 2501 thru 2503 plus 2598)(Line 25 above) | XXX | XXX | 0 | 0 |
| | | | | 0 | 0 |
| 3002 | | xxx | xxx | | |
| | | xxx | | | |
| | ummary of remaining write-ins for Line 30 from overflow page | | | | 0 |
| | | | | | |
| 3099. T | otals (Lines 3001 thru 3003 plus 3098)(Line 30 above) | XXX | XXX | 0 | 0 |

STATEMENT OF REVENUE AND EXPENSES

| | | Current | Vear | Prior Year |
|----------------|---|---|---------------|---------------|
| | | 1 Uncovered | 2 Total | 3 Total |
| 1. | Member Months. | | | 5, 179, 311 |
| 2. | Net premium income (including \$0 non-health premium income) | xxx | 6.368.144.084 | 5.513.801.635 |
| 3. | Change in unearned premium reserves and reserve for rate credits | | | |
| 4. | Fee-for-service (net of \$0 medical expenses) | | | 0 |
| 5. | Risk revenue | | | |
| 6. | Aggregate write-ins for other health care related revenues | | | 0 |
| 7. | Aggregate write-ins for other non-health revenues | | | |
| 8. | Total revenues (Lines 2 to 7) | | | |
| 0. | Hospital and Medical: | , | | |
| 9. | Hospital/medical benefits | 270,011,565 | 4,770,614,512 | 3,947,399,906 |
| 10. | Other professional services | 10,872,929 | 192,104,918 | 182, 156, 901 |
| 11. | Outside referrals | ļo ļ. | 0 | 0 |
| 12. | Emergency room and out-of-area | 7,330,686 | 129,519,916 | 95,874,554 |
| 13. | Prescription drugs | 18,153,927 | 320,746,985 | 269,593,289 |
| 14. | Aggregate write-ins for other hospital and medical. | 0 | 0 | 0 |
| 15. | Incentive pool, withhold adjustments and bonus amounts | 0 | 59,566,600 | 82,018,318 |
| 16. | Subtotal (Lines 9 to 15) | | | |
| | Less: | | | |
| 17. | Net reinsurance recoveries | 0 | 0 | 0 |
| 18. | Total hospital and medical (Lines 16 minus 17) | 306,369,107 | 5,472,552,930 | 4,577,042,968 |
| 19. | Non-health claims (net) | 0 | 0 | 0 |
| 20. | Claims adjustment expenses, including \$178,380,115 cost containment expenses | 0 | 204,471,335 | 169,390,602 |
| 21. | General administrative expenses | 0 | 545,872,571 | 599,873,472 |
| 22. | Increase in reserves for life and accident and health contracts (including \$0 | | | |
| | increase in reserves for life only) | 0 | 0 | 0 |
| 23. | Total underwriting deductions (Lines 18 through 22) | 306,369,107 | 6,222,896,836 | 5,346,307,041 |
| 24. | Net underwriting gain or (loss) (Lines 8 minus 23) | xxx | 145,247,248 | 167,494,594 |
| 25. | Net investment income earned (Exhibit of Net Investment Income, Line 17) | 0 | 24,416,423 | 25, 164, 906 |
| 26. | Net realized capital gains (losses) less capital gains tax of \$1,591,211 | 0 | 5,715,101 | 7,305,925 |
| 27. | Net investment gains (losses) (Lines 25 plus 26) | 0 | 30,131,525 | 32,470,832 |
| 28. | Net gain or (loss) from agents' or premium balances charged off [(amount recovered | | | |
| | \$0) (amount charged off \$ | 0 | 0 | 0 |
| 29. | Aggregate write-ins for other income or expenses | 0 | 58 | 49 |
| 30. | Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29) | xxx | 175,378,830 | 199,965,474 |
| 31. | Federal and foreign income taxes incurred | xxx | 34,839,994 | 59,851,954 |
| 32. | Net income (loss) (Lines 30 minus 31) | xxx | 140,538,837 | 140,113,520 |
| | DETAILS OF WRITE-INS | | | |
| 0601. | | xxx | 0 | 0 |
| 0602. | | xxx | | |
| 0603 | | xxx | | |
| 0698. | Summary of remaining write-ins for Line 6 from overflow page | xxx | 0 | 0 |
| 0699. | Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above) | XXX | 0 | 0 |
| 0701. | | XXX | 0 | 0 |
| 0702. | | | | |
| 0703 | | | | |
| 0798. | Summary of remaining write-ins for Line 7 from overflow page | | | 0 |
| 0799. | Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above) | XXX | 0 | 0 |
| 1401. | | | 0 | 0 |
| 1402. 1403. | | | | |
| 1403. 1498. | Summary of remaining write-ins for Line 14 from overflow page | | 0 | n |
| 1490. | Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above) | 0 | 0 | 0 |
| 2901. | Miscellaneous Income | 1 | 58 | 49 |
| 2902. | misser unious mount | | | |
| 2903 | | | | |
| 2998. | Summary of remaining write-ins for Line 29 from overflow page | | 0 | 0 |
| 2999. | Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above) | 0 | 58 | 49 |

STATEMENT OF REVENUE AND EXPENSES (Continued)

| 1 | STATEMENT OF REVENUE AND EXPENSES | Continueu | , |
|-------|--|-------------------|-----------------|
| | | 1 Current Year | 2 Prior Year |
| | | | |
| | | | |
| | CAPITAL AND SURPLUS ACCOUNT | | |
| | | | |
| | | | |
| 33. | Capital and surplus prior reporting year. | 879,045,229 | 716 , 768 , 438 |
| 34. | Net income or (loss) from Line 32 | | |
| 35. | Change in valuation basis of aggregate policy and claim reserves | | |
| | | | |
| 36. | Change in net unrealized capital gains (losses) less capital gains tax of \$ | | |
| 37. | Change in net unrealized foreign exchange capital gain or (loss) | | |
| 38. | Change in net deferred income tax | | |
| 39. | Change in nonadmitted assets | | |
| 40 | Change in unauthorized and certified reinsurance | | |
| 41. | Change in treasury stock | | |
| 42. | Change in surplus notes | 0 | 0 |
| 43. | Cumulative effect of changes in accounting principles. | 0 | 0 |
| 44. | Capital Changes: | | |
| | 44.1 Paid in | 0 | 0 |
| | 44.2 Transferred from surplus (Stock Dividend) | 0 | 0 |
| | 44.3 Transferred to surplus. | 0 | 0 |
| 45. | Surplus adjustments: | | |
| | 45.1 Paid in | | 30,000,000 |
| | 45.2 Transferred to capital (Stock Dividend) | 0 | 0 |
| | 45.3 Transferred from capital | | 0 |
| 46. | Dividends to stockholders | (75,000,000) | 0 |
| 47. | Aggregate write-ins for gains or (losses) in surplus | 0 | 0 |
| 48. | Net change in capital and surplus (Lines 34 to 47) | | 162,276,791 |
| 49. | Capital and surplus end of reporting period (Line 33 plus 48) | 912,923,407 | 879,045,229 |
| | DETAILS OF WRITE-INS | | |
| 4701. | | 0 | 0 |
| 4701. | | | |
| | | | |
| 4703. | Cummany of completing units ing fact ing 47 from quadray ages | | |
| 4798. | Summary of remaining write-ins for Line 47 from overflow page | | 0 |
| 4799. | Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above) | 0 | 0 |

CASH FLOW

| | CASH FLOW | 1 4 1 | 0 |
|-----|--|---------------|---------------|
| | | 1 | 2 |
| | | Current Year | Prior Year |
| | Cash from Operations | 0.004.055.040 | 5 474 507 500 |
| 1. | Premiums collected net of reinsurance | | |
| 2. | Net investment income | | 29,348,076 |
| 3. | Miscellaneous income | | U |
| 4. | Total (Lines 1 through 3) | | 5,500,945,672 |
| 5. | Benefit and loss related payments | | 4,376,193,281 |
| 6. | Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts | | 0 |
| 7. | Commissions, expenses paid and aggregate write-ins for deductions | | |
| 8. | Dividends paid to policyholders | | |
| 9. | Federal and foreign income taxes paid (recovered) net of \$2,813,728 tax on capital gains (losses) | | 61,415,067 |
| 10. | Total (Lines 5 through 9) | | 5,258,391,549 |
| 11. | Net cash from operations (Line 4 minus Line 10) | 135,960,515 | 242,554,123 |
| | Cash from Investments | | |
| 12. | Proceeds from investments sold, matured or repaid: | | |
| | 12.1 Bonds | 410,465,153 | 387,286,001 |
| | 12.2 Stocks | 0 | 0 |
| | 12.3 Mortgage loans | 0 | 0 |
| | 12.4 Real estate | 0 | 0 |
| | 12.5 Other invested assets | 0 | 0 |
| | 12.6 Net gains or (losses) on cash, cash equivalents and short-term investments | (612) | 16, 143 |
| | 12.7 Miscellaneous proceeds | 5,000 | 2,789,563 |
| | 12.8 Total investment proceeds (Lines 12.1 to 12.7) | 410,469,541 | 390,091,708 |
| 13. | Cost of investments acquired (long-term only): | | |
| | 13.1 Bonds | 675,277,512 | 560,771,566 |
| | 13.2 Stocks | 0 | 0 |
| | 13.3 Mortgage loans | 0 | 0 |
| | 13.4 Real estate | 0 | 0 |
| | 13.5 Other invested assets | 0 | 0 |
| | 13.6 Miscellaneous applications | 2,789,264 | 5,000 |
| | 13.7 Total investments acquired (Lines 13.1 to 13.6) | 678,066,776 | 560,776,566 |
| 14. | Net increase (decrease) in contract loans and premium notes | 0 | 0 |
| 15. | Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14) | (267,597,235) | (170,684,858) |
| | Cash from Financing and Miscellaneous Sources | | ļ |
| 16. | Cash provided (applied): | | |
| | 16.1 Surplus notes, capital notes | 0 | 0 |
| | 16.2 Capital and paid in surplus, less treasury stock | | 30,000,000 |
| | 16.3 Borrowed funds | 0 | 0 |
| | 16.4 Net deposits on deposit-type contracts and other insurance liabilities | | 0 |
| | 16.5 Dividends to stockholders | | |
| | 16.6 Other cash provided (applied) | | (20,861,010) |
| 17. | Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6) | | 9,138,990 |
| | DECONCILIATION OF CASH CASH EQUIVALENTS AND SHOOT TEDM INVESTMENTS | | |
| 18. | RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17) | (207,984,067) | 81,008,255 |
| 19. | Cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17) | (201,004,007) | 01,000,200 |
| 13. | 19.1 Beginning of year | 353,106,165 | 272,097,911 |
| | 19.2 End of year (Line 18 plus Line 19.1) | 145,122,099 | 353, 106, 165 |
| | 10.2 End of year (Line 10 pido Enne 10.1) | 170, 122,000 | 000, 100, 100 |

| Note: Supplemental disclosures of cash flow information for non-cash transactions: | | |
|--|--|---|
| | | i |

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

| Net premium income | | Ai | MALI SIS C | | THOMO D | LINEO | DOCINI | _00 | | | |
|--|---|---------------|----------------------|------------|---------|-------|---------|---------------|----------|--------------|------------|
| Total Conferente National Conference | | 1 | 2 | 3 | 4 | 5 | Federal | | Ü | 9 | 10 |
| 1 Net permism in measured premism in reserves unit reserves (not of a control o | | T.1.1 | | | | | Health | XVIII | XIX | 01111111- | Other |
| 2. Change in interacting interactive performance secretive 0 0 0 0 0 0 0 0 0 | A Not construction to | | (Hospital & Medical) | Supplement | Only | | | | Medicaid | Otner Health | Non-Health |
| Table Credit | | | l | | | LD | υ | | | υ | μυ |
| Medical expenses | rate credit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4. Risk revenue (Lines in for other inhalf) care related | | | | | | | | | | | |
| 5 | | 0 | 0 | 0 | 0 | 0 | 0 | ļ0 ļ. | 0 | 0 | XXX |
| revenues | | 0 | 0 | 0 | 0 | 0 | 0 | ļ0 ļ. | 0 | 0 | XXX |
| Privarience | | 0 | 0 | | 0 | 0 | o | Δ | 0 | 0 | xxx |
| 8. Hospitalmedical benefits | | 0 | xxx | xxx | XXX | xxx | XXX | xxx | xxx | XXX | 0 |
| 8 Hospital/medical benefits | 7. Total revenues (Lines 1 to 6) | 6,368,144,084 | 0 | 0 | 0 | 0 | 0 | 6,368,144,084 | 0 | 0 | 0 |
| 9 Other professional services | | | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | XXX |
| 10 Outside referrals | | | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | XXX |
| 11 Emergency room and out-of-sarea | 10. Outside referrals | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | XXX |
| 12 Prescription drugs | 11. Emergency room and out-of-area | 129,519,916 | 0 | 0 | 0 | 0 | 0 | 129,519,916 | 0 | 0 | XXX |
| 14 Incentive pool, withhold adjustments and bronus amounts 59,986,00 | | | 0 | 0 | 0 | 0 | 0 | 320,746,985 | 0 | 0 | XXX |
| 14 Incentive pool, withhold adjustments and bronus amounts 59,986,00 | 13. Aggregate write-ins for other hospital and medical | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | XXX |
| 16 Net reinsurance recoveries | | 59,566,600 | 0 | 0 | 0 | 0 | 0 | 59,566,600 | 0 | 0 | XXX |
| 17 Total medical and hospital (Lines 15 minus 16) | 15. Subtotal (Lines 8 to 14) | 5,472,552,930 | 0 | 0 | 0 | 0 | 0 | 5,472,552,930 | 0 | 0 | XXX |
| 18. Non-health claims (net) | 16. Net reinsurance recoveries | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | XXX |
| 18. Non-health claims (net) | 17. Total medical and hospital (Lines 15 minus 16) | 5,472,552,930 | 0 | 0 | 0 | 0 | 0 | 5,472,552,930 | 0 | 0 | XXX |
| \$ | 18. Non-health claims (net) | 0 | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | 0 |
| \$ | 19. Claims adjustment expenses including | | | | | | | | | | |
| 20 General administrative expenses 5.45,872,571 0 0 0 0 0 0 0 5.54,872,571 0 0 0 0 0 0 0 0 0 | \$178,380,115 cost containment expenses | 204,471,335 | 0 | 0 | 0 | 0 | 0 | 204,471,335 | 0 | 0 | 0 |
| 21 Increase in reserves for accident and health contracts | | 545,872,571 | 0 | 0 | 0 | 0 | 0 | 545,872,571 | 0 | 0 | 0 |
| 23. Total underwriting deductions (Lines 17 to 22) | 21. Increase in reserves for accident and health contracts | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | XXX |
| 24. Total underwriting gain or (loss) (Line 7 minus Line 23) 145,247,248 0 0 0 0 0 145,247,248 0 0 0 0 0 0 0 0 0 | 22. Increase in reserves for life contracts | 0 | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | 0 |
| DETAILS OF WRITE-INS | 23. Total underwriting deductions (Lines 17 to 22) | 6,222,896,836 | 0 | 0 | 0 | 0 | 0 | 6,222,896,836 | 0 | 0 | 0 |
| 0501 0502 0503 | 24. Total underwriting gain or (loss) (Line 7 minus Line 23) | 145,247,248 | 0 | 0 | 0 | 0 | 0 | 145,247,248 | 0 | 0 | 0 |
| 0502 0503 0598 Summary of remaining write-ins for Line 5 from overflow page 0 0 0 0 0 0 0 0 0 | | | | | | | | | | | |
| 0503 0508 Summary of remaining write-ins for Line 5 from overflow page | | | | | | | | | | | XXX |
| 0598. Summary of remaining write-ins for Line 5 from overflow page | | | | | | | | | | | XXX |
| page Dotals (Lines 0501 thru 0503 plus 0598) (Line 5 above) Dotals (Lines 0501 thru 0503 plus 0598) (Line 5 above) Dotals (Lines 0501 thru 0503 plus 0598) (Line 5 above) Dotals (Lines 0501 thru 0503 plus 0598) (Line 5 above) Dotals (Lines 0501 thru 0503 plus 0598) (Line 5 above) Dotals (Lines 0501 thru 0503 plus 0598) (Line 6 above) Dotals (Lines 0501 thru 0503 plus 0598) (Line 0508) (Line | | | | | | | | | | | XXX |
| 0601 | page | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | xxx |
| 0602 | 0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | XXX |
| 0603. | 0601. | | XXX | XXX | XXX | XXX | XXX | xxx | XXX | XXX | |
| 0698. Summary of remaining write-ins for Line 6 from overflow page 0 XXX | | | | XXX | | | | xxx | | XXX | |
| page 0 XXX | | | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | |
| 0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above) 0 XXX | | | | | | | | | | | |
| 1301. | page | 0 | | | | | | | | | 0 |
| 1302. | | 0 | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | 0 |
| 1303. | 5.5 | | ļ | | | | | ļ | | | XXX |
| 1398. Summary of remaining write-ins for Line 13 from overflow page 0 0 0 0 0 0 XXX | | | ļ | | | | | ļ | | | XXX |
| overflow page 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | | | | | | | - | | | | XXX |
| | overflow page | 0 | 0 | 0 | 0 | 0 | 0 | Δ | 0 | 0 | xxx |
| 1399. Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above) 0 0 0 0 0 0 XX | 1399. Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | XXX |

7

UNDERWRITING AND INVESTMENT EXHIBIT PART 1 - PREMIUMS

| PART 1 - PREMIUMS | 1 | 2 | 2 | 4 |
|---|--------------------|------------------------|----------------------|--|
| Line of Business | Direct Business | Reinsurance Assumed | Reinsurance Ceded | Net Premium Income (Cols. 1 + 2 - 3) |
| Comprehensive (hospital and medical) | 0 | 0 | 0 | 0 |
| 2. Medicare Supplement | 0 | 0 | 0 | 0 |
| 3. Dental only | 0 | 0 | 0 | 0 |
| 4. Vision only | 0 | 0 | 0 | 0 |
| 5. Federal Employees Health Benefits Plan | 0 | 0 | 0 | 0 |
| 6. Title XVIII - Medicare | 6,368,144,084 | 0 | 0 | 6,368,144,084 |
| 7. Title XIX - Medicaid | 0 | 0 | 0 | 0 |
| 8. Other health | 0 | 0 | 0 | 0 |
| 9. Health subtotal (Lines 1 through 8) | 6,368,144,084 | 0 | 0 | 6,368,144,084 |
| 10. Life | 0 | 0 | 0 | 0 |
| 11. Property/casualty | 0 | 0 | 0 | 0 |
| 12. Totals (Lines 9 to 11) | 6,368,144,084 | 0 | 0 | 6,368,144,084 |

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

| | | | | PART 2 - CLA | IMS INCURRED DO | KING THE TEAK | | | | | |
|-----|---|--------------------------|---------------------------------------|------------------------|-----------------|---------------|--------------------------------------|---|--------------------------|--------------|---------------------|
| | | 1 | 2 | 3 | 4 | 5 | 6 Federal | 7 | 8 | 9 | 10 |
| | | Total | Comprehensive (Hospital & Medical) | Medicare Supplement | Dental Only | Vision Only | Employees Health Benefits Plan | Title XVIII Medicare | Title XIX Medicaid | Other Health | Other Non-Health |
| 1. | Payments during the year: | | | | | | | | | | |
| | 1.1 Direct | 5,407,598,304 | 0 | 0 | 0 | 0 | 0 | 5,407,598,304 | 0 | 0 | 0 |
| İ | 1.2 Reinsurance assumed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 L | 0 |
| | 1.3 Reinsurance ceded | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 L | 0 |
| | 1.4 Net | 5,407,598,304 | 0 | 0 | 0 | 0 | 0 | 5,407,598,304 | 0 | 0 | 0 |
| 2. | Paid medical incentive pools and bonuses | 75,653,190 | 0 | 0 | 0 | 0 | 0 | 75,653,190 | 0 | 0 | 0 |
| 3. | | | | | - | | | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | | | |
| 0. | 3.1 Direct | 644,340,560 | 0 | 0 | 0 | 0 | 0 | 644,340,560 | 0 | 0 | 0 |
| | 3.2 Reinsurance assumed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 3.3 Reinsurance ceded | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | 3.4 Net | 644,340,560 | 0 | 0 | 0 | | 0 | 644,340,560 | 0 | 0 | |
| 4 | Claim reserve December 31, current year from Part 2D: | | | | | | | | | | |
| ٦. | 4.1 Direct | 0 | ١ | 0 | ۱ | 0 | 0 | ١ | ١ | ا ۱ | n |
| | 4.2 Reinsurance assumed | | n l | | n l | | n | n l | | n l | |
| | 4.3 Reinsurance ceded | ٥ | o | ٥ | Λ | ٥ | o | n | | | |
| | 4.4 Net | | Λ | ٠ | Λ | ٥ | Λ | Λ | | | |
| _ | | 0 | | | | | | U | | | |
| 5. | vear | 75, 125,513 | ا ۱ | 0 | ١ | 0 | 0 | 75, 125, 513 | 0 | ا ۱ | 0 |
| 6. | , | 70,764,986 | n l | | n l | | 0 | 70,764,986 | | n | |
| _ | Amounts recoverable from reinsurers December 31, | | | | | | | | | | |
| ١. | current year | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| l a | Claim liability December 31, prior year from Part 2A: | - | | | | | - | | | | |
| J . | 8.1 Direct | 568, 187, 547 | 0 | 0 | 0 | 0 | 0 | 568, 187, 547 | 0 | 0 | 0 |
| | 8.2 Reinsurance assumed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 8.3 Reinsurance ceded | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 8.4 Net | 568, 187, 547 | 0 | 0 | 0 | 0 | 0 | 568,187,547 | 0 | 0 | |
| 9. | | | | | | | | | | | |
| 3. | 9.1 Direct | 0 | ١ | 0 | ١ | 0 | 0 | 0 | 0 | ا ۱ | 0 |
| | 9.2 Reinsurance assumed | ٥ | n l | ٥ | n l | ٥ | n | n | | | |
| | 9.3 Reinsurance ceded | ٥ | n | ٠ | ο Λ | ٥ | o | n | | n | |
| | 9.4 Net | ٠٠ | n l | ٥ | o | ٥ | o | n | | | |
| 10 | Accrued medical incentive pools and bonuses, prior year | 91,212,103 | o | | Λ | ٥ | 0 | 91.212.103 | | | |
| 10. | Amounts recoverable from reinsurers December 31, | 31,212,100 | 0 | <u> </u> | U | <u> </u> | 0 | 31,212,100 | 0 | • | |
| 11. | prior year | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ا ۱ | 0 |
| 12 | Incurred Benefits: | • | | | <u> </u> | | † | † | | • | |
| 12. | 12.1 Direct | 5,412,986,330 | n l | 0 | n l | n | 0 | 5,412,986,330 | 0 | n l | n |
| | 12.2 Reinsurance assumed | n | n l | N | n l | n | n | n | n l | n l | o |
| | 12.3 Reinsurance ceded | n | n l | n | n l | n | n | n l | n | n | |
| | 12.4 Net | 5,412,986,330 | 0 | 0 | 0 | 0 | 0 | 5,412,986,330 | 0 | n | |
| 13. | | 59,566,600 | 0 | 0 | 0 | 0 | <u> </u> | | 0 | 0 | |
| 13. | incurred medical incentive pools and bonuses | 000,000, 0 00 | U | U | U | U | 1 | 39,300,600 | U | U [| · |

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

| , | | | | 13 LIABILIT END | | | | | | , |
|---|------------------|--------------------------------------|-----------------------------|-----------------|------------------|--|---------------------------------|-------------------------------|-------------------|---|
| | 1 Total | 2 Comprehensive (Hospital & Medical) | 3 Medicare Supplement | 4 Dental Only | 5 Vision Only | 6 Federal Employees Health Benefits Plan | 7 Title XVIII Medicare | 8 Title XIX Medicaid | 9 Other Health | 10 Other Non-Health |
| Reported in Process of Adjustment: | | | | | | | | | | |
| 1.1 Direct | 200,565,102 | ١ | 0 | 0 | | , | 200,565,102 | 0 | 0 | ١ |
| 1.2 Reinsurance assumed | 200,303,102 | 0 | 0 | | 0 | | 200,303,102 | | | |
| | | | | | | 0 | 0 | 0 | | |
| 1.3 Reinsurance ceded | | I | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1.4 Net | 200,565,102 | 0 | 0 | 0 | 0 | 0 | 200,565,102 | 0 | 0 | 0 |
| Incurred but Unreported: 2.1 Direct | | 0 | 0 | 0 | 0 | 0 | 302,012,326 | 0 | 0 | 0 |
| | | | 0 | | 0 | | | 0 | | 0 |
| 2.2 Reinsurance assumed | | | | U | U | 0 | 0 | U | 0 | 0 |
| 2.3 Reinsurance ceded | 0 | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2.4 Net | 302,012,326 | 0 | 0 | 0 | 0 | 0 | 302,012,326 | 0 | 0 | 0 |
| Amounts Withheld from Paid Claims and Capitations: 3.1 Direct | 141,763,132 | | 0 | 0 | 0 | 0 | 141,763,132 | 0 | 0 | 0 |
| 3.2 Reinsurance assumed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3.3 Reinsurance ceded | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3.4 Net | 141,763,132 | 0 | 0 | 0 | 0 | 0 | 141,763,132 | 0 | 0 | 0 |
| 4. TOTALS: 4.1 Direct | 644,340,560 0 | 0 | 0 | 0 | 0 | 0 | 644,340,560 0 | 0 | 0 | 0 |
| 4.4 Net | 644,340,560 | 0 | 0 | 0 | 0 | 0 | 644,340,560 | 0 | 0 | 0 |
| 1.11100 | 511,010,000 | | | | <u> </u> | | 511,010,000 | · | | |

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

| | Claims Paid [| Ouring the Year | Claim Reserve a December 31 o | nd Claim Liability of Current Year | 5 | 6 | |
|---|------------------------------------|------------------------------------|----------------------------------|---------------------------------------|-----------------------------------|--------------------------------------|--|
| | 1 | 2 | 3 | 4 | | Estimated Claim Reserve and Claim | |
| | On Claims Incurred | | On Claims Unpaid | | Claims Incurred | Liability | |
| Line of Business | Prior to January 1 of Current Year | On Claims Incurred During the Year | December 31 of Prior Year | On Claims Incurred During the Year | In Prior Years (Columns 1 + 3) | December 31 of Prior Year | |
| Comprehensive (hospital and medical) | 0 | 0 | 0 | 0 | 0 | 0 | |
| Medicare Supplement | 0 | 0 | 0 | 0 | 0 | 0 | |
| 3. Dental Only | 0 | 0 | 0 | 0 | 0 | 0 | |
| 4. Vision Only | 0 | 0 | 0 | 0 | 0 | 0 | |
| 5. Federal Employees Health Benefits Plan | 0 | 0 | 0 | 0 | 0 | 0 | |
| 6. Title XVIII - Medicare | | 5,071,169,755 | 57,648,854 | 586,691,706 | 394,077,404 | 568,187,547 | |
| 7 Title XIX - Medicaid | 0 | 0 | 0 | 0 | 0 | 0 | |
| 8. Other health | 0 | 0 | 0 | 0 | 0 | 0 | |
| 9. Health subtotal (Lines 1 to 8) | 336,428,549 | 5,071,169,755 | 57,648,854 | 586,691,706 | 394,077,404 | 568,187,547 | |
| 10. Healthcare receivables (a) | 0 | 168,310,274 | 0 | 0 | 0 | 97,545,287 | |
| 11. Other non-health | 0 | 0 | 0 | 0 | 0 | 0 | |
| 12. Medical incentive pools and bonus amounts | 75,653,190 | 0 | 12,514,485 | 62,611,028 | 88 , 167 , 675 | 91,212,103 | |
| 13. Totals (Lines 9 - 10 + 11 + 12) | 412,081,739 | 4,902,859,481 | 70,163,339 | 649,302,734 | 482,245,079 | 561,854,363 | |

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XVIII

| | | Cun | nulative Net Amounts P | aid | |
|------------------------------------|---------|-----------|------------------------|-----------|-----------|
| | 1 | 2 | 3 | 4 | 5 |
| Year in Which Losses Were Incurred | 2017 | 2018 | 2019 | 2020 | 2021 |
| 1. Prior | | 55,176 | 55,281 | 55,186 | 55,186 |
| 2. 2017 | 676,280 | 718,786 | 717, 190 | 717,314 | 717,026 |
| 3. 2018 | XXX | 2,635,321 | 2,848,985 | 2,846,913 | 2,846,461 |
| 4. 2019 | xxx | xxx | 3,332,824 | 3,690,948 | 3,684,687 |
| 5. 2020 | xxx | xxx | XXX | 4,020,354 | 4,439,437 |
| 6. 2021 | XXX | XXX | XXX | XXX | 5,071,170 |

Section B - Incurred Health Claims - Title XVIII

| | Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and I Outstanding at End of Year | | | | |
|------------------------------------|---|-----------|-----------|-----------|-----------|
| | 1 2 3 4 | | | | |
| Year in Which Losses Were Incurred | 2017 | 2018 | 2019 | 2020 | 2021 |
| 1. Prior | 57,916 | 55,367 | 55,281 | 55, 186 | 55,186 |
| 2. 2017 | 724,151 | 719,126 | 717,350 | 717,314 | 717,026 |
| 3. 2018 | xxx | 2,928,748 | 2,859,564 | 2,847,234 | 2,846,461 |
| 4. 2019 | xxx | XXX | 3,761,293 | 3,699,037 | 3,685,658 |
| 5. 2020 | xxx | XXX | XXX | 4,671,344 | 4,508,629 |
| 6. 2021 | xxx | XXX | XXX | XXX | 5,720,472 |

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---------------------------------|-----------------|----------------|------------------|------------|--------------------|------------|---------------|---------------|-------------------|------------|
| | | | | | Claim and Claim | | | | Total Claims and | |
| Years in which | | | | | Adjustment Expense | | | Unpaid Claims | Claims Adjustment | |
| Premiums were Earned and Claims | | | Claim Adjustment | (Col. 3/2) | Payments | (Col. 5/1) | | Adjustment | Expense Incurred | (Col. 9/1) |
| were Incurred | Premiums Earned | Claims Payment | Expense Payments | Percent | (Col. 2 + 3) | Percent | Claims Unpaid | Expenses | (Col. 5+7+8) | Percent |
| 1. 2017 | 803,575 | 717,026 | 6,819 | 1.0 | 723,845 | 90.1 | 0 | 0 | 723,845 | 90.1 |
| 2. 2018 | 3,417,678 | 2,846,461 | 27,070 | 1.0 | 2,873,531 | 84.1 | 0 | 0 | 2,873,531 | 84.1 |
| 3. 2019 | 4,345,828 | 3,684,687 | 35,041 | 1.0 | 3,719,728 | 85.6 | 971 | 6 | 3,720,705 | 85.6 |
| 4. 2020 | 5,513,802 | 4,439,437 | 42,219 | 1.0 | 4,481,656 | 81.3 | 69,192 | 392 | 4,551,240 | 82.5 |
| 5. 2021 | 6,368,144 | 5,071,170 | 48,227 | 1.0 | 5,119,397 | 80.4 | 649,303 | 3,679 | 5,772,379 | 90.6 |

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

(\$000 Omitted) Section A - Paid Health Claims - Grand Total

| | | | Cur | nulative Net Amounts F | Paid | |
|----|------------------------------------|---------|-----------|------------------------|-----------|-----------|
| | | 1 | 2 | 3 | 4 | 5 |
| | Year in Which Losses Were Incurred | 2017 | 2018 | 2019 | 2020 | 2021 |
| 1. | Prior | 56,597 | 55,176 | 55,281 | 55, 186 | 55,186 |
| 2. | 2017 | 676,280 | 718,786 | 717, 190 | 717,314 | 717,026 |
| 3. | 2018 | xxx | 2,635,321 | 2,848,985 | 2,846,913 | 2,846,461 |
| 4. | 2019 | xxx | xxx | 3,332,824 | 3,690,948 | 3,684,687 |
| 5. | 2020 | xxx | xxx | XXX | 4,020,354 | 4,439,437 |
| 6. | 2021 | XXX | XXX | XXX | XXX | 5,071,170 |

Section B - Incurred Health Claims - Grand Total

| | Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Outstanding at End of Year | | | | | |
|------------------------------------|--|-----------|-----------|-----------|-----------|--|
| | 1 2 3 4 | | | | | |
| Year in Which Losses Were Incurred | 2017 | 2018 | 2019 | 2020 | 2021 | |
| 1. Prior | 57,916 | 55,367 | 55,281 | 55 , 186 | 55 , 186 | |
| 2. 2017 | 724 , 151 | 719,126 | 717,350 | 717,314 | 717,026 | |
| 3. 2018 | XXX | 2,928,748 | 2,859,564 | 2,847,234 | 2,846,461 | |
| 4. 2019 | xxx | XXX | 3,761,293 | 3,699,037 | 3,685,658 | |
| 5. 2020 | XXX | XXX | xxx | 4,671,344 | 4,508,629 | |
| 6. 2021 | XXX | XXX | XXX | XXX | 5,720,472 | |

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

| | | 1 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
|----|---------------------------------|-----------------|----------------|------------------|------------|--------------------|------------|---------------|---------------|-------------------|------------|--|
| | | | | | | Claim and Claim | | | | Total Claims and | | |
| | Years in which | | | | | Adjustment Expense | | | Unpaid Claims | Claims Adjustment | | |
| | Premiums were Earned and Claims | | | Claim Adjustment | (Col. 3/2) | Payments | (Col. 5/1) | | Adjustment | Expense Incurred | (Col. 9/1) | |
| | were Incurred | Premiums Earned | Claims Payment | Expense Payments | Percent | (Col. 2 + 3) | Percent | Claims Unpaid | Expenses | (Col. 5+7+8) | Percent | |
| 1. | 2017 | 803,575 | 717,026 | 6,819 | 1.0 | 723,845 | 90.1 | 0 | 0 | 723,845 | 90.1 | |
| 2. | 2018 | 3,417,678 | 2,846,461 | 27,070 | 1.0 | 2,873,531 | 84.1 | 0 | 0 | 2,873,531 | 84.1 | |
| 3. | 2019 | 4,345,828 | 3,684,687 | 35,041 | 1.0 | 3,719,728 | 85.6 | 971 | 6 | 3,720,705 | 85.6 | |
| 4. | 2020 | 5,513,802 | 4,439,437 | 42,219 | 1.0 | 4,481,656 | 81.3 | 69,192 | 392 | 4,551,240 | 82.5 | |
| 5. | 2021 | 6,368,144 | 5,071,170 | 48,227 | 1.0 | 5,119,397 | 80.4 | 649,303 | 3,679 | 5,772,379 | 90.6 | |

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

| | PART 2D - A | GGREGATE RESER | VE FOR ACCIDENT | AND HEALTH CO | NTRACTS ONLY | | | | |
|---|-------------|--------------------------------------|-----------------------------|----------------|------------------|--|---------------------------------|-------------------------------|------------|
| | 1 Total | 2 Comprehensive (Hospital & Medical) | 3 Medicare Supplement | 4 Dental Only | 5 Vision Only | 6 Federal Employees Health Benefits Plan | 7 Title XVIII Medicare | 8 Title XIX Medicaid | 9 Other |
| Unearned premium reserves | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Additional policy reserves (a) | 0 | L0 | 0 | 0 | L0 | 0 | 0 | 0 | 0 |
| Reserve for future contingent benefits | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserve for rate credits or experience rating refunds (including | | | | | | | | | |
| \$0) for investment income | 12,590,536 | 0 | 0 | 0 | 0 | 0 | 12,590,536 | 0 | 0 |
| Aggregate write-ins for other policy reserves | 15,309,721 | 0 | 0 | 0 | 0 | 0 | 15,309,721 | 0 | 0 |
| 6. Totals (gross) | 27,900,257 | 0 | 0 | 0 | 0 | 0 | 27,900,257 | 0 | 0 |
| 7. Reinsurance ceded | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 8. Totals (Net)(Page 3, Line 4) | 27,900,257 | 0 | 0 | 0 | 0 | 0 | 27,900,257 | 0 | 0 |
| Present value of amounts not yet due on claims | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 10. Reserve for future contingent benefits | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 11. Aggregate write-ins for other claim reserves | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 12. Totals (gross) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 13. Reinsurance ceded | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 14. Totals (Net)(Page 3, Line 7) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DETAILS OF WRITE-INS | | | | | | | | | |
| 0501. Risk Adjustment Premium Payable | 15,309,721 | 0 | 0 | 0 | 0 | 0 | 15,309,721 | 0 | 0 |
| 0502. | | | | | | | | | |
| 0503. | | | | | | | | | |
| 0598. Summary of remaining write-ins for Line 5 from overflow page | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above) | 15,309,721 | 0 | 0 | 0 | 0 | 0 | 15,309,721 | 0 | 0 |
| 1101. | | | | | | | | | |
| 1102. | | | | | | | | | |
| 1103. | | | | | | | | | |
| 1198. Summary of remaining write-ins for Line 11 from overflow page | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1199. Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

(a) Includes \$ ______0 premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

| | | | SIS OF EXPENSE | | 4 | |
|------------|---|---------------------------------|---------------------------------------|---------------------------------------|------------------------|------------|
| | - | Claim Adjustme 1 | nt Expenses 2 | 3 | 4 | 5 |
| | | Cost Containment Expenses | Other Claim Adjustment Expenses | General Administrative Expenses | Investment Expenses | Total |
| 1. | Rent (\$0 for occupancy of | | | | | |
| | own building) | 1 , 193 , 195 | 261,941 | 3,935,550 | 7,710 | 5,398,39 |
| 2. | Salary, wages and other benefits | 98,269,544 | 10,242,000 | 176,904,434 | 342,849 | 285,758,8 |
| 3. | Commissions (less \$0 | | | | | |
| | ceded plus \$ | 0 | 0 | 149 995 663 | 6 201 | 150 001 8 |
| 4. | Legal fees and expenses | | | | | |
| 5. | Certifications and accreditation fees | | | | | |
| 6. | Auditing, actuarial and other consulting services | | | | | 10,342,1 |
| 7. | Traveling expenses | | | 933,126 | | , , |
| 8. | Marketing and advertising | | , i | ´ | <i>′</i> | 31,390,1 |
| | Postage, express and telephone | | | | | |
| 9. | | | | | | 26,025,3 |
| 10. | Printing and office supplies | | | | | 4,893,7 |
| 11. | Occupancy, depreciation and amortization | | | | | |
| 12. | Equipment | 482,769 | 105,981 | 1,592,324 | 3,119 | 2, 184, 1 |
| 13. | Cost or depreciation of EDP equipment and software | 6,609,302 | 1,449,991 | 21,811,182 | 629 | 29,871,1 |
| 14. | Outsourced services including EDP, claims, and other services | 46, 191, 151 | 8,830,138 | 104,739,112 | 196,252 | 159,956,6 |
| 15. | Boards, bureaus and association fees | | | 980,632 | | |
| 16. | Insurance, except on real estate | ´ | • | • | · | |
| 17. | Collection and bank service charges | | | | | 3,897,8 |
| 18. | Group service and administration fees | | | | | |
| 19. | Reimbursements by uninsured plans | | | | | |
| | Reimbursements from fiscal intermediaries | | | | | |
| 20. | Real estate expenses | | | | | |
| 21. | · | | | | | |
| 22. | Real estate taxes | | 0 | 0 | 0 | |
| 23. | Taxes, licenses and fees: | | | (000 == 4) | | /aaa = |
| | 23.1 State and local insurance taxes | | | | | (688,7 |
| | 23.2 State premium taxes | | | 0 | | |
| | 23.3 Regulatory authority licenses and fees | | | 2,845,804 | | |
| | 23.4 Payroll taxes | 0 | 0 | 11, 153, 130 | 21,630 | 11, 174, 7 |
| | 23.5 Other (excluding federal income and real estate taxes) | 0 | 0 | 1,038,887 | 425 | 1,039,3 |
| 24. | Investment expenses not included elsewhere | | | | 582,913 | |
| 25. | Aggregate write-ins for expenses | 502,117 | 110,230 | 3,808,023 | 2,006 | 4,422,3 |
| | Total expenses incurred (Lines 1 to 25) | | | 545,872,571 | | |
| 26. | | | | 8,778,249 | [| • |
| 27. | Less expenses unpaid December 31, current year | | | | | 12,855,0 |
| 28. 29. | Amounts receivable relating to uninsured plans. | | | | | 11,366,1 |
| 30. | Amounts receivable relating to uninsured plans, | | 0 | | | 33,442,9 |
| 31. | Total expenses paid (Lines 26 minus 27 plus 28 | 0 | 0 070 044 | 49,985,435 | 1 000 407 | 49,985,4 |
| | minus 29 plus 30) | 178,380,115 | 25,979,941 | 561,037,521 | 1,292,487 | 766,690,0 |
| | DETAILS OF WRITE-INS | | | | | |
| 2501. | Miscellaneous Administrative Expenses | | 110,230 | 3,808,023 | 2,006 | 4,422,3 |
| 2502. | | | | | | |
| 2503. | | | | | | |
| 2598. | Summary of remaining write-ins for Line 25 from overflow page | 0 | 0 | 0 | 0 | |
| 599 | Totals (Lines 2501 thru 2503 plus 2598)(Line 25 | 502,117 | 110,230 | 3,808,023 | 2,006 | 4,422,3 |

14

EXHIBIT OF NET INVESTMENT INCOME

| | | 1 | 2 |
|-------|---|-----------------------|---------------------------------------|
| | | Collected During Year | Earned During Yea |
| 1. | U.S. government bonds | (a)126,161 | |
| 1.1 | Bonds exempt from U.S. tax | (a)0 | |
| 1.2 | Other bonds (unaffiliated) | . , , , , | |
| 1.3 | Bonds of affiliates | (a)0 | |
| 2.1 | Preferred stocks (unaffiliated) | (b)0 | |
| 2.11 | Preferred stocks of affiliates | | |
| 2.2 | Common stocks (unaffiliated) | | |
| 2.21 | Common stocks of affiliates | | |
| 3. | Mortgage loans | (c)0 | |
| 4. | Real estate | | |
| 5 | Contract Loans | 0 | |
| 6 | Cash, cash equivalents and short-term investments | (e)335,061 | 334 , 50 |
| 7 | Derivative instruments | (f)0 | |
| 8. | Other invested assets | 0 | |
| 9. | Aggregate write-ins for investment income | 2,654 | 2,6 |
| 10. | Total gross investment income | 24,660,295 | 25,708,9 |
| 11. | Investment expenses | | (g)1,266,8 |
| 12. | Investment taxes, licenses and fees, excluding federal income taxes | | (g)25,6 |
| 13. | Interest expense | | (h) |
| 14. | Depreciation on real estate and other invested assets | | (i) |
| 15. | Aggregate write-ins for deductions from investment income | | |
| 16. | Total deductions (Lines 11 through 15) | | 1,292,4 |
| 17. | Net investment income (Line 10 minus Line 16) | | 24,416,4 |
| | DETAILS OF WRITE-INS | | |
| 0901. | Miscellaneous Investment Income | 2.654 | 2.6 |
| 0902. | | , , , , | |
| 0903. | | | |
| 0998. | Summary of remaining write-ins for Line 9 from overflow page | | |
| 0999. | Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above) | 2.654 | 2.6 |
| 1501. | | 1 | · · · · · · · · · · · · · · · · · · · |
| 1502. | | | |
| 1503. | | | |
| 1598. | Summary of remaining write-ins for Line 15 from overflow page | | |
| 1599. | Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above) | | |
| 1099. | Totals (Lilies 1501 tillu 1505 plus 1580) (Lilie 15, above) | | <u> </u> |

| (α) molados φ | | adordar or allocatic loop \$ | promiam and 1000 ¢ | para for accided interest on parchaece. |
|-----------------|-------------------|--|--|---|
| (b) Includes \$ | 0 | accrual of discount less \$0 amortization of | premium and less \$0 | paid for accrued dividends on purchases |
| (c) Includes \$ | 0 | accrual of discount less \$0 amortization of | premium and less \$0 | paid for accrued interest on purchases. |
| (d) Includes \$ | 0 | for company's occupancy of its own buildings; and excludes | \$0 interest on encu | mbrances. |
| (e) Includes \$ | 304,591 | accrual of discount less \$16,725 amortization of | premium and less \$148,453 | paid for accrued interest on purchases. |
| (f) Includes \$ | 0 | accrual of discount less \$0 amortization o | f premium. | |
| | and Separate Acco | investment expenses and \$ | taxes, licenses and fees, excluding fede | eral income taxes, attributable to |
| (h) Includes \$ | 0 | interest on surplus notes and \$0 interest of | n capital notes. | |
| (i) Includes \$ | 0 | depreciation on real estate and \$0 depreciation | ciation on other invested assets. | |

EXHIBIT OF CAPITAL GAINS (LOSSES)

| | | 4 | | - (LOCCL | | |
|-------|--|----------------------|----------------|------------------------|--------------------|----------------------|
| | | 1 | 2 | 3 | 4 | 5 |
| | | | | | | |
| | | | | | | |
| | | | | Total Realized Capital | Change in | Change in Unrealized |
| | | Realized Gain (Loss) | Other Realized | Gain (Loss) | Unrealized Capital | Foreign Exchange |
| | | On Sales or Maturity | Adjustments | (Columns 1 + 2) | Gain (Loss) | Capital Gain (Loss) |
| 1. | U.S. Government bonds | 289,111 | 0 | 289,111 | 0 | 0 |
| 1.1 | Bonds exempt from U.S. tax | 0 | 0 | 0 | 0 | 0 |
| 1.2 | Other bonds (unaffiliated) | 7,017,813 | 0 | 7,017,813 | (288,935) | 0 |
| 1.3 | Bonds of affiliates | 0 | 0 | 0 | 0 | 0 |
| 2.1 | Preferred stocks (unaffiliated) | l0 l | 0 | 0 | 0 | 0 |
| 2.11 | Preferred stocks of affiliates | 0 | 0 | 0 | 0 | 0 |
| 2.2 | Common stocks (unaffiliated) | 0 | 0 | 0 | 0 | 0 |
| 2.21 | Common stocks of affiliates | 0 | 0 | 0 | 0 | 0 |
| 3. | Mortgage loans | 0 | 0 | 0 | 0 | 0 |
| 4. | Real estate | 0 <u> </u> | 0 | 0 | 0 | 0 |
| 5. | Contract loans | 0 | 0 | 0 | 0 | 0 |
| 6. | Cash, cash equivalents and short-term investments | (612) | 0 | (612) | 0 | 0 |
| 7. | Derivative instruments | 0 | 0 | 0 | 0 | 0 |
| 8. | Other invested assets | 0 | 0 | 0 | 0 | 0 |
| 9. | Aggregate write-ins for capital gains (losses) | 0 | 0 | 0 | 0 | 0 |
| 10. | Total capital gains (losses) | 7,306,313 | 0 | 7,306,313 | (288,935) | 0 |
| | DETAILS OF WRITE-INS | | | | | |
| 0901. | | | | | | |
| 0902. | | | | | | |
| 0903. | | | | | | |
| 0998. | Summary of remaining write-ins for Line 9 from overflow page | 0 | 0 | 0 | 0 | 0 |
| 0999. | Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above) | 0 | 0 | 0 | 0 | 0 |

EXHIBIT OF NON-ADMITTED ASSETS

| | | 1 | 2 | 3 Change in Total |
|----------------|---|--|--|---|
| | | Current Year Total Nonadmitted Assets | Prior Year Total Nonadmitted Assets | Nonadmitted Assets (Col. 2 - Col. 1) |
| 1. | Bonds (Schedule D) | _ | 0 | 0 |
| 2. | Stocks (Schedule D): | | | |
| | 2.1 Preferred stocks | 0 | 0 | 0 |
| | 2.2 Common stocks | | 0 | 1 |
| 3. | Mortgage loans on real estate (Schedule B): | | | |
| ٥. | 3.1 First liens | 0 | 0 | 0 |
| | 3.2 Other than first liens. | | | 0 |
| 4. | Real estate (Schedule A): | | | |
| ٦. | 4.1 Properties occupied by the company | 0 | 0 | 0 |
| | 4.2 Properties held for the production of income. | | | 0 |
| | 4.3 Properties held for sale | | | 0 |
| 5. | Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA) | | | 0 |
| 6. | Contract loans | | | 1 |
| 7. | Derivatives (Schedule DB) | | | i |
| 8. | Other invested assets (Schedule BA) | | | 1 |
| o. 9. | Receivables for securities | | | 1 |
| | Securities lending reinvested collateral assets (Schedule DL) | | | |
| 10. 11. | Aggregate write-ins for invested assets (Scriedule DL) | | | |
| | | | | 1 |
| 12. | Subtotals, cash and invested assets (Lines 1 to 11) | | | |
| 13. | Title plants (for Title insurers only) | | | |
| 14. | Investment income due and accrued | . 0 | 0 | 0 |
| 15. | Premiums and considerations: | | | |
| | 15.1 Uncollected premiums and agents' balances in the course of collection | | | |
| | 15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due | | | |
| | 15.3 Accrued retrospective premiums and contracts subject to redetermination | . 0 | 0 | 0 |
| 16. | Reinsurance: | | | |
| | 16.1 Amounts recoverable from reinsurers | | | 0 |
| | 16.2 Funds held by or deposited with reinsured companies | | | 0 |
| | 16.3 Other amounts receivable under reinsurance contracts | | 0 | 0 |
| 17. | Amounts receivable relating to uninsured plans | | 0 | 0 |
| 18.1 | Current federal and foreign income tax recoverable and interest thereon | 0 | 0 | 0 |
| 18.2 | Net deferred tax asset | 736,479 | 708,621 | (27,858 |
| 19. | Guaranty funds receivable or on deposit | 0 | 0 | 0 |
| 20. | Electronic data processing equipment and software | | 0 | 0 |
| 21. | Furniture and equipment, including health care delivery assets | 0 | 0 | 0 |
| 22. | Net adjustment in assets and liabilities due to foreign exchange rates | | 0 | 0 |
| 23. | Receivable from parent, subsidiaries and affiliates | | | |
| 24. | Health care and other amounts receivable | | | (27,845,972 |
| 25. | Aggregate write-ins for other than invested assets | | | (11,863,779 |
| 26. | Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25) | | | |
| 27. | From Separate Accounts, Segregated Accounts and Protected Cell Accounts | | 0 | 0 |
| 28. | Total (Lines 26 and 27) | 73, 194, 618 | 34,270,823 | (38,923,795 |
| | DETAILS OF WRITE-INS | | | |
| 1101. | | 0 | 0 | 0 |
| 1102. | | | | |
| 1103. | | | | |
| 1198. | Summary of remaining write-ins for Line 11 from overflow page | 0 | 0 | 0 |
| 1199. | Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above) | 0 | 0 | 0 |
| 2501. | Prepaid Expenses | - | - | |
| 2502. | Prepaid Commissions | | | |
| 2502. 2503. | Provider Contracts | | | |
| | Summary of remaining write-ins for Line 25 from overflow page | | | 1 |
| 2598. | Summary of remaining write-ins for Line 25 from overflow page | 34,067,316 | 22,203,537 | 1 |

17

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

| EXTIBIT 1 ETTTO BUT TO BUT | Total Members at End of | | | | | | |
|--|-------------------------|--------------------|---------------------|--------------------|-------------------|-------------------------------|--|
| Source of Enrollment | 1 Prior Year | 2 First Quarter | 3 Second Quarter | 4 Third Quarter | 5 Current Year | Current Year Member Months | |
| Health Maintenance Organizations | 427,113 | 446,624 | 453 , 170 | 460,645 | 461,196 | 5,444,575 | |
| Provider Service Organizations | 0 | 0 | 0 | 0 | 0 | 0 | |
| Preferred Provider Organizations | 18,397 | 14,955 | 15,925 | 16,805 | 17,067 | 191,108 | |
| 4. Point of Service | 0 | 13,429 | 13,463 | 13,463 | 13,442 | 161,312 | |
| 5. Indemnity Only | 0 | 0 | 0 | 0 | 0 | 0 | |
| Aggregate write-ins for other lines of business | 0 | 0 | 0 | 0 | 0 | 0 | |
| 7. Total | 445,510 | 475,008 | 482,558 | 490,913 | 491,705 | 5,796,995 | |
| DETAILS OF WRITE-INS | | | | | | | |
| 0601. | | | | | | | |
| 0602. | | | | | | | |
| 0603. | | | | | | | |
| 0698. Summary of remaining write-ins for Line 6 from overflow page | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above) | 0 | 0 | 0 | 0 | 0 | 0 | |

NOTES TO THE FINANCIAL STATEMENTS

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The financial statements of the Company are presented on the basis of accounting practices prescribed or permitted by the Washington Office of Insurance.

The Washington Office of Insurance (the Office) recognizes only statutory accounting practices prescribed or permitted by the State of Washington for determining and reporting the financial condition and results of operations of an insurance company, for determining its solvency under the Washington Insurance Law. The National Association of Insurance Commissioners' (NAIC) Accounting Practices and Procedures manual (NAIC SSAP) has been adopted as a component of prescribed or permitted practices by the State of Washington. The Commissioner of Insurance has the right to permit other specific practices that deviate from prescribed practices. No deviations from the Codification currently exist.

A reconciliation of the Company's net income and capital and surplus between NAIC SSAP and practices prescribed and permitted by the State of Washington is shown below:

| | SSAP# | F/S Page | F/S Line # | | 2021 | 2020 |
|--|-------|----------|------------|----|-------------|-------------------|
| Net Income | | | | - | | |
| Arcadian Health Plan, Inc. Washington basis | XXX | XXX | XXX | \$ | 140,538,837 | \$ 140,113,520 |
| 2. State Prescribed Practices that is an increase/(decrease) NAIC SSAP | | | | | - | - |
| 3. State Permitted Practices that is an increase/(decrease) NAIC SSAP | | | | | - | - |
| 4. NAIC SSAP | XXX | XXX | XXX | \$ | 140,538,837 | \$ 140,113,520 |
| Surplus | | | | | | |
| 5. Arcadian Health Plan, Inc. Washington basis | XXX | XXX | XXX | \$ | 912,923,407 | \$ 879,045,229 |
| 6. State Prescribed Practices that is an increase/(decrease) NAIC SSAP | | | | | - | - |
| 7. State Permitted Practices that is an increase/(decrease) NAIC SSAP | | | | | - | - |
| 8. NAIC SSAP | XXX | XXX | XXX | \$ | 912,923,407 | \$ 879,045,229 |

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with Statutory Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. It also requires disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results could differ from those estimates.

C. Accounting Policy

Premiums are reported as earned in the period in which members are entitled to receive services, and are net of retroactive membership adjustments. Retroactive membership adjustments result from enrollment changes not yet processed, or not yet reported by an employer group or the government. Premiums received prior to such period are recorded as advance premiums.

Benefits incurred and loss adjustment expenses include claim payments, capitation payments, pharmacy costs net of rebates, allocations of certain centralized expenses, legal and administrative costs to settle claims, and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care provided prior to the date of the statements of admitted assets, liabilities and surplus. Capitation payments represent monthly contractual fees disbursed to participating primary care physicians, and other providers who are responsible for providing medical care to members. Pharmacy costs represent payments for members' prescription drug benefits, net of rebates from drug manufacturers.

In addition, the Company uses the following accounting policies:

- (1) Short-term investments include investments mainly in U.S. Government obligations with a maturity of twelve months or less from the date of purchase. Short-term investments are recorded at amortized cost. The carrying value of short-term investments approximates fair value due to the short-term maturities of the investments.
- (2-4) Investments are valued and classified in accordance with methods prescribed by the NAIC. Bonds with an NAIC rating of 1 or 2 are carried at amortized cost, with all other bonds being recorded at the lower of amortized cost or fair value; redeemable preferred stocks are carried at amortized cost; and non-redeemable preferred stocks are carried at fair value.

The Company regularly evaluates investment securities for impairment. For all securities other than loan-backed and structured securities, the Company considers factors affecting the investee, factors affecting the industry the investee operates within, and general debt and equity market trends. The Company also considers the length of time an investment's fair value has been below carrying value, the near term prospects for recovery to carrying value, and the Company's intent and ability to hold the investment until maturity or market recovery is realized. If and when a determination is made that a decline in fair value below the cost basis is other-than-temporary, the related investment is written down to its estimated fair value through earnings.

Amortization of bond premium or discount is computed using the scientific interest method.

Income from investments is recorded on an accrual basis. For the purpose of determining realized gains and losses, the cost of securities sold is based upon specific identification. Investment income due and accrued over 90 days past due is nonadmitted.

NOTES TO THE FINANCIAL STATEMENTS

- (5) Not Applicable.
- For loan backed and structured securities where the securities fair value is less than the amortized cost, the Company considers several factors to determine if the security's impairment is other-than-temporary. If the Company has the intent to sell the security or if the Company does not have the intent and ability to retain the security until recovery of its fair value, the related investment is written down to its estimated fair value through earnings. If, however, the Company has the intent and ability to retain the security until recovery of its fair value, the Company considers factors affecting the investee, factors affecting the industry the investee operates within, and general debt and equity market trends. The Company also considers the length of time an investment's fair value has been below carrying value and the near term prospects for recovery to carrying value. If the determination is made, based on these factors, that the Company does expect to recover the entire amortized cost of the security, then an other-than-temporary impairment has not occurred. If, however, the determination is made that the Company does not expect to recover the entire amortized cost of the security based on the factors noted above, the Company recognizes a realized loss in earnings for the non-interest related decline. No loss is recognized for the interest impairment.
- (7) Not Applicable.
- (8) Not Applicable.
- (9) Not Applicable.
- (10-11) The estimates of future medical benefit payments are developed using actuarial methods and assumptions based upon claim payment patterns, medical cost inflation, historical development such as claim inventory levels and claim receipt patterns, and other relevant factors. Corresponding administrative costs to process outstanding claims are estimated and accrued. Estimates of future payments relating to services incurred in the current and prior periods are continually reviewed by management and adjusted as necessary.

The Company assesses the profitability of its contracts for providing health insurance coverage to its members when current operating results or forecasts indicate probable future losses. The Company records a premium deficiency liability in current operations to the extent that the sum of expected future medical costs, claim adjustment expenses and maintenance costs exceed related future premiums. Investment income is not contemplated in the calculation of the premium deficiency liability.

Management believes the Company's benefits payable and loss adjustment expense are adequate to cover future claims and loss adjustment expense payments required, however, such estimates are based on knowledge of current events and anticipated future events and, therefore, the actual liability could differ from the amounts provided.

(12) The Company has not modified its capitalization policy from the prior period.

Equipment is stated at cost less accumulated depreciation. Depreciation expense is computed using the straight-line method over estimated useful lives generally ranging from three to five years. Improvements to leased facilities are depreciated over the shorter of the remaining lease term or the anticipated life of the improvement.

The Company recognizes an asset or liability for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements. The temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled.

- (13) The Company estimates anticipated Pharmacy Rebate Receivables using the analysis of historical recovery patterns.
- (14) Not Applicable.
- (15) Not Applicable.
- D. Going Concern

Management of the Company has evaluated the Company's ability to continue as a going concern under SSAP No. 1, *Accounting Policies, Risks & Uncertainties, and Other Disclosures* (SSAP No. 1). Based on this evaluation, Management has determined that there is no substantial doubt about the Company's ability to continue as a going concern.

2. Accounting Changes and Corrections of Errors

Not Applicable.

- 3. <u>Business Combinations and Goodwill</u>
 - A. Statutory Purchase Method

Not Applicable.

B. Statutory Merger

Not Applicable.

C. Assumption Reinsurance

Not Applicable.

NOTES TO THE FINANCIAL STATEMENTS

D. Impairment Loss

Not Applicable.

E. Subcomponents and Calculation of Adjusted Surplus and Total Admitted Goodwill

Not Applicable.

4. <u>Discontinued Operations</u>

Not Applicable.

- Investments
 - A. Mortgage Loans, Including Mezzanine Real Estate Loans

Not Applicable.

B. Debt Restructuring

Not Applicable.

C. Reverse Mortgages

Not Applicable.

- D. Loan-Backed Securities
 - Prepayment assumptions for mortgage-backed/loan-backed and structured securities were obtained from industry market sources.
 - (2) Not Applicable.
 - (3) Not Applicable.
 - (4) The Company does not have any investments in an other-than-temporary impairment position at December 31, 2021.

Gross unrealized losses and related fair value of temporarily impaired securities that have been in a continuous unrealized loss position were as follows at December 31, 2021:

(a) The aggregate amount of unrealized losses:

Less than Twelve Months
 Twelve Months or Longer
 (7,402,847)
 (419,844)

(b) The aggregate related fair value of securities with unrealized losses:

Less than Twelve Months
 Twelve Months or Longer
 391,894,018
 9,304,581

- (5) Unrealized losses are primarily due to increases in market interest rates and tighter liquidity conditions in the current markets than when the securities were purchased. All issuers of securities trading at an unrealized loss remain current on all contractual payments and the Company believes it is probable that all amounts due according to the contractual terms of the debt securities are collectible. After taking into account these and other factors, including the severity of the decline and the Company's ability and intent to hold these securities until recovery or maturity, the Company determined the unrealized losses on these investment securities were temporary and, as such, no impairment was required.
- E. Dollar Repurchase Agreements and/or Securities Lending Transactions
 - (1) The Company has no repurchase agreements or securities lending transactions.
 - (2) The Company has not pledged any of its assets as collateral.
 - (3-7) Not Applicable.
- F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

Not Applicable.

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

Not Applicable.

H. Repurchase Agreements Transactions Accounted for as a Sale

Not Applicable.

I. Reverse Repurchase Agreements Transactions Accounted for as a Sale

Not Applicable.

J. Real Estate

NOTES TO THE FINANCIAL STATEMENTS

Not Applicable.

K. Low-Income Housing Tax Credits (LIHTC)

Not Applicable.

- L. Restricted Assets
 - (1) Restricted Assets (Including Pledged)

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|--|---|---|--|--|--|--|--|
| Restricted Asset Category | Total Gross (Admitted & Nonadmitted) Restricted from Current Year | Total Gross (Admitted & Nonadmitted) Restricted from Prior Year | Increase/ (Decrease) (1 minus 2) | Total Current Year Nonadmitted Restricted | Total Current Year Admitted Restricted (1 minus 4) | Percentage Gross (Admitted & Nonadmitted) Restricted to Total Assets (a) | Percentage Admitted Restricted to Total Admitted Assets (b) |
| Subject to contractual | | | | | | | |
| obligation for which | | | | | | | |
| liability is not shown | \$ - | \$ - | \$ - | \$ - | \$ - | -% | -% |
| b. Collateral held under | | | | | | | |
| security lending agreements | | | | | | | |
| c. Subject to repurchase | - | - | - | - | - | · - | - |
| agreements | _ | _ | _ | _ | _ | | _ |
| d. Subject to reverse | | | | | | | |
| repurchase agreements | - | - | - | - | - | - | - |
| e. Subject to dollar | | | | | | | |
| repurchase agreements | - | - | - | - | - | - | - |
| f. Subject to dollar reverse | | | | | | | |
| repurchase agreements | - | - | - | - | - | - | - |
| g. Placed under option | | | | | | | |
| contracts h. Letter stock or securities | - | - | - | - | - | - | - |
| restricted to sale – | | | | | | | |
| excluding FHLB | | | | | | | |
| capital stock | _ | _ | _ | _ | | | _ |
| i. FHLB capital | | | | | | | |
| stock | - | - | - | - | - | | - |
| On deposit with states | 11,508,922 | 11,601,925 | (93,003) | - | 11,508,922 | 0.63% | 0.66% |
| k. On deposit with other | | | | | | | |
| regulatory bodies | - | - | - | - | - | - | - |
| l. Pledged collateral to | | | | | | | |
| FHLB (including assets backing funding | | | | | | | |
| agreements) | _ | _ | _ | _ | _ | | _ |
| m. Pledged as collateral not | | | | | | | |
| captured in other | | | | | | | |
| categories | - | - | _ | - | - | | - |
| n. Other restricted assets | | = | - | = | - | <u> </u> | = |
| o. Total Restricted Assets | \$ 11,508,922 | \$ 11,601,925 | \$ (93,003) | - | \$ 11,508,922 | 0.63% | 0.66% |

Detail of Assets Pledged as Collateral Not Captured in Other Categories (Contracts that Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate)

Not Applicable.

Detail of Other Restricted Assets Categories (Contracts that Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate)

Not Applicable.

Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements

Not Applicable.

M. Working Capital Finance Investments

Not Applicable.

N. Offsetting and Netting of Assets and Liabilities

Not Applicable.

O. 5GI* Securities

Not Applicable.

P. Short Sales

(2)

Not Applicable.

Q. Prepayment Penalty and Acceleration Fees

Number of CUSIPS Aggregate Amount of Investment Income

89,541

\$

NOTES TO THE FINANCIAL STATEMENTS

R. Share of Cash Pool by Asset Type

Not Applicable.

6. <u>Joint Ventures, Partnerships and Limited Liability Companies</u>

- A. The Company has no investments in Joint Ventures, Partnerships or Limited Liability Companies that exceed 10.0 percent of its admitted assets.
- B. The Company did not recognize any impairment write down for its investments in Joint Ventures, Partnerships and Limited Liability Companies during the statement periods.

7. <u>Investment Income</u>

A. Due and accrued income was excluded from surplus on the following basis:

All investment income due and accrued with amounts that are over 90 days past due with the exception of mortgage loans in default.

B. The total amount excluded was \$0.

8. <u>Derivative Instruments</u>

Not Applicable.

9. <u>Income Taxes</u>

A. Deferred Tax Assets/(Liabilities)

(1) The components of the net admitted deferred tax asset/(liability) by tax character were as follows:

| | | | D | ecem | ber 31, 2021 | | |
|----------|---|----|------------|-------|--------------|----|------------|
| | | | Ordinary | | Capital | | Total |
| a. | Gross deferred tax assets | \$ | 18,604,184 | \$ | 62,026 | \$ | 18,666,210 |
| b. | Statutory valuation allowance adjustments | | - | | (62,026) | | (62,026) |
| c. | Adjusted gross deferred tax assets | | 18,604,184 | | - | | 18,604,184 |
| d. | Deferred tax assets nonadmitted | | (736,479) | | _ | | (736,479) |
| e. | Net admitted deferred tax assets | | 17,867,705 | | - | | 17,867,705 |
| f. | Deferred tax liabilities | | (38,940) | | - | | (38,940) |
| g. | Net admitted deferred tax asset/(liability) | \$ | 17,828,765 | \$ | - | \$ | 17,828,765 |
| | | | D | lacam | ber 31, 2020 | | |
| | | | Ordinary | ecem | Capital | | Total |
| a. | Gross deferred tax assets | \$ | 11,058,818 | \$ | 1,350 | \$ | 11,060,168 |
| a. b. | Statutory valuation allowance adjustments | Ψ | 11,030,010 | Ψ | (1,350) | Ψ | (1,350) |
| c. | Adjusted gross deferred tax assets | - | 11,058,818 | | (1,330) | | 11,058,818 |
| d. | Deferred tax assets nonadmitted | | (708,621) | | _ | | (708,621) |
| e. | Net admitted deferred tax assets | - | 10,350,197 | | _ | | 10,350,197 |
| f. | Deferred tax liabilities | | (45,645) | | _ | | (45,645) |
| g. | Net admitted deferred tax asset/(liability) | \$ | 10,304,552 | \$ | - | \$ | 10,304,552 |
| U | • | | | | | | |
| | | | | (| Change | | |
| | | | Ordinary | | Capital | | Total |
| a. | Gross deferred tax assets | \$ | 7,545,366 | \$ | 60,676 | \$ | 7,606,042 |
| b. | Statutory valuation allowance adjustments | | - | | (60,676) | | (60,676) |
| c. | Adjusted gross deferred tax assets | | 7,545,366 | | - | | 7,545,366 |
| d. | Deferred tax assets nonadmitted | | (27,858) | | - | | (27,858) |
| e. | Net admitted deferred tax assets | | 7,517,508 | | - | | 7,517,508 |
| f. | Deferred tax liabilities | | 6,705 | | - | | 6,705 |
| g. | Net admitted deferred tax asset/(liability) | \$ | 7,524,213 | \$ | - | \$ | 7,524,213 |

(2) The amount of admitted adjusted gross deferred tax assets under SSAP No. 101 were as follows:

| | | December 31, 2021 | | | | | |
|----|--|-------------------|------------|----|---------|----|-------------|
| | | | Ordinary | | Capital | | Total |
| a. | Federal income taxes paid in prior years recoverable through loss carrybacks | \$ | 17,190,490 | \$ | - | \$ | 17,190,490 |
| b. | Adjusted gross deferred tax assets expected to be realized after application of the | | | | | | |
| | threshold limitation | | 638,275 | | - | | 638,275 |
| 1. | Adjusted gross deferred tax assets expected to be realized following the Balance Sheet | | | | | | |
| | date | | XXX | | XXX | | 638,275 |
| 2. | Adjusted gross deferred tax assets allowed per limitation threshold | | XXX | | XXX | | 134,264,196 |
| c. | Adjusted gross deferred tax assets offset by | | | | | | |
| | gross deferred tax liabilities | | 38,940 | | - | | 38,940 |
| d. | Deferred tax assets admitted as the result of | | | | | | |
| | application of SSAP No. 101. Total | \$ | 17,867,705 | \$ | - 9 | \$ | 17,867,705 |

NOTES TO THE FINANCIAL STATEMENTS

| a. Federal income taxes paid in prior years recoverable through loss carrybacks b. Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation 1. Adjusted gross deferred tax assets allowed per limitation threshold 2. Adjusted gross deferred tax assets allowed application of SSAP No. 101. Total a. Federal income taxes paid in prior years recoverable through loss carrybacks b. Adjusted gross deferred tax assets allowed per limitation threshold c. Adjusted gross deferred tax assets allowed per limitation threshold c. Adjusted gross deferred tax assets offset by gross deferred tax assets admitted as the result of application of SSAP No. 101. Total a. Federal income taxes paid in prior years recoverable through loss carrybacks b. Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation 1. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date 2. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date 2. Adjusted gross deferred tax assets sellowed per limitation threshold c. Adjusted gross deferred tax assets allowed per limitation threshold c. Adjusted gross deferred tax assets allowed per limitation threshold c. Adjusted gross deferred tax assets allowed per limitation threshold c. Adjusted gross deferred tax assets allowed per limitation threshold c. Adjusted gross deferred tax assets allowed per limitation threshold c. Adjusted gross deferred tax assets allowed per limitation threshold c. Adjusted gross deferred tax assets allowed per limitation threshold c. Adjusted gross deferred tax assets allowed per limitation threshold c. Adjusted gross deferred tax assets offset by gross deferred tax assets allowed per limitation threshold c. Adjusted gross deferred tax assets offset by gross deferred tax assets allowed per limitation threshold c. Adjusted gross deferred tax assets offset by gross deferred tax assets offset by gross deferred tax assets offse | | December 31, 2020 | | | | |
|--|---|--|----|-----------|----|--|
| a. Federal income taxes paid in prior years recoverable through loss carrybacks b. Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation 1. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date 2. Adjusted gross deferred tax assets allowed per limitation threshold c. Adjusted gross deferred tax assets offset by gross deferred tax liabilities d. Deferred tax assets admitted as the result of application of SSAP No. 101. Total a. Federal income taxes paid in prior years recoverable through loss carrybacks b. Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation 1. Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation 2. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date 2. Adjusted gross deferred tax assets expected to be realized sollowing the Balance Sheet date 2. Adjusted gross deferred tax assets allowed per limitation threshold 3. Deferred tax assets offset by gross deferred tax assets offset by gross deferred tax assets offset by gross deferred tax assets allowed per limitation threshold 3. Deferred tax assets admitted as the result of the threshold threshold 3. Adjusted gross deferred tax assets allowed per limitation threshold 4. Adjusted gross deferred tax assets allowed per limitation threshold 5. Adjusted gross deferred tax assets offset by gross deferred tax assets allowed per limitation threshold 6. Deferred tax assets admitted as the result of the threshold threshold 6. Deferred tax assets admitted as the result of the threshold | | Ordinary | | Capital | | Total |
| to be realized after application of the threshold limitation 1. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date 2. Adjusted gross deferred tax assets allowed per limitation threshold 3. Deferred tax assets admitted as the result of application of SSAP No. 101. Total 4. Deferred tax assets admitted as the result of application of SSAP No. 101. Total 5. Adjusted gross deferred tax assets offset by gross deferred tax assets admitted as the result of application of SSAP No. 101. Total 6. Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation 7. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date 8. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date 9. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date 1. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date 2. Adjusted gross deferred tax assets allowed per limitation threshold 3. Capital 4. Deferred tax assets expected to be realized following the Balance Sheet date 4. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date 5. Adjusted gross deferred tax assets allowed per limitation threshold 6. Adjusted gross deferred tax assets offset by gross deferred tax liabilities 6. Deferred tax assets admitted as the result of | recoverable through loss carrybacks | \$ 10,103,801 | \$ | - | \$ | 10,103,801 |
| date XXX XXX 200,751 2. Adjusted gross deferred tax assets allowed per limitation threshold C. Adjusted gross deferred tax assets offset by gross deferred tax liabilities 45,645 | to be realized after application of the threshold limitation 1. Adjusted gross deferred tax assets expected | 200,751 | | - | | 200,751 |
| per limitation threshold c. Adjusted gross deferred tax assets offset by gross deferred tax liabilities d. Deferred tax assets admitted as the result of application of SSAP No. 101. Total a. Federal income taxes paid in prior years recoverable through loss carrybacks b. Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation 1. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date 2. Adjusted gross deferred tax assets allowed per limitation threshold c. Adjusted gross deferred tax assets offset by gross deferred tax liabilities d. Deferred tax assets admitted as the result of | date | XXX | | XXX | | 200,751 |
| gross deferred tax liabilities d. Deferred tax assets admitted as the result of application of SSAP No. 101. Total a. Federal income taxes paid in prior years recoverable through loss carrybacks b. Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation threshold lowing the Balance Sheet date 2. Adjusted gross deferred tax assets allowed per limitation threshold c. Adjusted gross deferred tax assets offset by gross deferred tax assets admitted as the result of d. Deferred tax assets admitted as the result of | per limitation threshold | XXX | | XXX | | 130,311,102 |
| d. Deferred tax assets admitted as the result of application of SSAP No. 101. Total Change Cordinary Capital Total | | 45,645 | | - | | 45,645 |
| a. Federal income taxes paid in prior years recoverable through loss carrybacks b. Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation 1. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date 2. Adjusted gross deferred tax assets allowed per limitation threshold 2. Adjusted gross deferred tax assets offset by gross deferred tax liabilities 3. Adjusted gross deferred tax assets offset by gross deferred tax assets offset by gross deferred tax assets admitted as the result of | d. Deferred tax assets admitted as the result of | \$ | \$ | - | \$ | , |
| a. Federal income taxes paid in prior years recoverable through loss carrybacks b. Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation 1. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date 2. Adjusted gross deferred tax assets allowed per limitation threshold 2. Adjusted gross deferred tax assets offset by gross deferred tax liabilities 3. Adjusted gross deferred tax assets offset by gross deferred tax assets offset by gross deferred tax assets admitted as the result of | | | | | | |
| recoverable through loss carrybacks \$ 7,086,689 \$ - \$ 7,086,689 b. Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation 437,524 - 437,524 1. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date XXX XXX 437,524 2. Adjusted gross deferred tax assets allowed per limitation threshold XXX XXX 3,953,094 c. Adjusted gross deferred tax assets offset by gross deferred tax liabilities (6,705) - (6,705) | | | | Change | | |
| to be realized after application of the threshold limitation 437,524 - 437,524 1. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date XXX XXX 437,524 2. Adjusted gross deferred tax assets allowed per limitation threshold XXX XXX 3,953,094 c. Adjusted gross deferred tax assets offset by gross deferred tax liabilities (6,705) - (6,705) d. Deferred tax assets admitted as the result of | | Ordinary | | U | | Total |
| to be realized following the Balance Sheet date XXX XXX 437,524 2. Adjusted gross deferred tax assets allowed per limitation threshold XXX XXX 3,953,094 c. Adjusted gross deferred tax assets offset by gross deferred tax liabilities (6,705) - (6,705) d. Deferred tax assets admitted as the result of | recoverable through loss carrybacks | \$ <u>, </u> | \$ | U | \$ | |
| per limitation threshold XXX XXX 3,953,094 c. Adjusted gross deferred tax assets offset by gross deferred tax liabilities (6,705) - (6,705) d. Deferred tax assets admitted as the result of | recoverable through loss carrybacks b. Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation | \$ 7,086,689 | \$ | U | \$ | 7,086,689 |
| gross deferred tax liabilities (6,705) - (6,705) d. Deferred tax assets admitted as the result of | recoverable through loss carrybacks b. Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation 1. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date | \$ 7,086,689 437,524 | \$ | Capital - | \$ | 7,086,689 437,524 |
| d. Deferred tax assets admitted as the result of | recoverable through loss carrybacks b. Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation 1. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date 2. Adjusted gross deferred tax assets allowed per limitation threshold | \$ 7,086,689 437,524 XXX | \$ | Capital - | \$ | 7,086,689 437,524 437,524 |
| | recoverable through loss carrybacks b. Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation 1. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet date 2. Adjusted gross deferred tax assets allowed per limitation threshold c. Adjusted gross deferred tax assets offset by | \$ 7,086,689 437,524 XXX XXX | \$ | Capital - | \$ | 7,086,689 437,524 437,524 3,953,094 |

(3) The ratio percentage used to determine recovery period and threshold limitation amount was as follows:

| | | December 31, 2021 | December 31, 2020 |
|----|--|-------------------|-------------------|
| a. | Ratio percentage used to determine recovery period | | |
| | and threshold limitation amount | 548% | 633% |
| b. | Amount of adjusted capital and surplus used to | | |
| | determine recovery period and threshold limitation | | |
| | in 2 b.2 above | 895,094,642 | 868,740,677 |

(4) The impact of tax planning strategies on adjusted gross DTAs and net admitted DTAs was as follows:

| | | ber 31, 2 | |
|---|------------------|-----------|---------|
| | Ordinary | | Capital |
| Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage | | | |
| 1. Adjusted gross DTAs amount from note 9A1(c) | \$ 18,604,184 | \$ | - |
| Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies Net admitted adjusted gross DTAs amount from note | 0.00% | | 0.00% |
| 9A1(e) 4. Percentage of net admitted adjusted gross DTAs by tax | \$ 17,867,705 | \$ | - |
| Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies | 0.00% | | 0.00% |
| | Decem | ber 31, 2 | 2020 |
| | Ordinary | 001 51, 2 | Capital |
| a. Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage | J | | • |
| 1. Adjusted gross DTAs amount from note 9A1(c) | \$ 11,058,818 | \$ | - |
| Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies Net admitted adjusted gross DTAs amount from note | 0.00% | | 0.00% |
| 9A1(e) | \$ 10,350,197 | \$ | - |
| Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies | 0.00% | | 0.00% |
| - | | | |
| | Ordinary | Change | Capital |
| Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage | | | |
| 1. Adjusted gross DTAs amount from note 9A1(c) | \$ 7,545,366 | \$ | - |
| 2. Percentage of adjusted gross DTAs by tax character | 0.005 | | 0.000/ |
| attributable to the impact of tax planning strategies 3. Net admitted adjusted gross DTAs amount from note | 0.00% | | 0.00% |
| 9A1(e) | \$ 7,517,508 | \$ | - |

NOTES TO THE FINANCIAL STATEMENTS

4. Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies

0.00% 0.00%

- b. Does the Company's tax planning strategies include the use of reinsurance? Yes $[\]$ No $[\ X\]$
- B. There are no temporary differences for which a DTL has not been established.
- C. Current and deferred income taxes
 - (1) Current income taxes incurred consist of the following major components:

| | | December 31, 2021 | December 31, 2020 | Change |
|----------|--|-----------------------|-------------------|--------------|
| a. | Federal | \$ 34,842,150 | \$ 59,852,803 | (25,010,653) |
| b. | Foreign | - | - | - |
| c. | Subtotal | 34,842,150 | 59,852,803 | (25,010,653) |
| d. e. | Federal income tax on net capital gains Utilization of capital loss | 1,591,211 | 2,200,822 | (609,611) |
| | carryforwards | - | - | - |
| f. | Other | (2,156) | (849) | (1,307) |
| g. | Federal and foreign income taxes incurred | \$ 36,431,205 | \$ 62,052,776 | (25,621,571) |

NOTES TO THE FINANCIAL STATEMENTS

(2–3) The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities are as follows:

DTAs resulting from Book/Tax Differences in:

| resu a. | Iting from Book/Tax Differences in: Ordinary | December 31, 2021 | December 31, 2020 | Change |
|------------|---|----------------------|-------------------|-----------|
| | Discounting of unpaid losses | \$ 6,255,327 \$ | | (804,675) |
| | 2. Unearned premium reserve | 205,519 | 152,148 | 53,371 |
| | 3. Policyholder reserves | | | |
| | 4. Investments and other | - | - | _ |
| | 5. Deferred acquisition costs | - | - | _ |
| | 6. Policyholder dividends accrual | - | _ | _ |
| | 7. Fixed assets | _ | _ | _ |
| | 8. Compensation and benefit accruals | 936 | 1,083 | (147) |
| | 9. Pension accruals | - | - | - |
| | 10. Receivables – nonadmitted | - | - | - |
| | 11. Net operating loss carry-forward | - | - | - |
| | 12. Tax credit carry-forward | - | - | - |
| | 13. Other | 1,208,230 | 1,392 | 1,206,838 |
| | 14. Bad debts | 7,403,813 | 1,730,308 | 5,673,505 |
| | 15. Accrued litigation | - | _ | - |
| | 16. CMS Rx reserve | 2,008,405 | 476,107 | 1,532,298 |
| | 17. CMS risk corridor -ACA | - | - | - |
| | 18. Medicare risk adjustment data | - | - | - |
| | 19. Miscellaneous reserves | 4,939 | 203,933 | (198,994) |
| | 20. Accrued lease | - | - | _ |
| | 21. Section 197 intangible | - | _ | - |
| | 22. Premium rebates MER | - | - | - |
| | 23. Provider contracts | 1,517,015 | 1,433,845 | 83,170 |
| | 24. Premium acquisition expense | - | - | - |
| | 99. Subtotal | 18,604,184 | 11,058,818 | 7,545,366 |
| b. | Statutory valuation allowance | , , | , , | , |
| | adjustment | - | - | - |
| c. | Nonadmitted | (736,479) | (708,621) | (27,858) |
| d. | Admitted Ordinary DTAs | 17,867,705 | 10,350,197 | 7,517,508 |
| e. | Capital | | | |
| | 1. Investments | 62,026 | 1,350 | 60,676 |
| | 2. Net capital loss carry-forward | - | - | - |
| | 3. Real estate | - | - | - |
| | 4. Other | - | - | - |
| f. | 99. Subtotal Statutory valuation allowance | 62,026 | 1,350 | 60,676 |
| | adjustment | (62,026) | (1,350) | (60,676) |
| g. | Nonadmitted | - | - | - |
| h. | Admitted capital DTAs | - | - | - |
| i. | Admitted DTAs | \$ 17,867,705 \$ | 10,350,197 \$ | 7,517,508 |

NOTES TO THE FINANCIAL STATEMENTS

DTLs resulting from Book/Tax Differences in:

| 1L3 | a. | Ordinary | December 31, 2021 | December 31, 2020 | Change |
|-----|-----|---|--------------------------|---------------------|-----------|
| | | 1. Investments | \$ - | \$ - \$ | - |
| | | 2. Fixed assets3. Deferred and uncollected | - | - | - |
| | | premium 4. Policyholder reserves/salvage & subrogation | - | - | - |
| | | 5. Other | - | - | - |
| | | 6. Premium acquisition reserve | (3,491) | (1,334) | (2,157) |
| | | 7. Bad debts | - | - | - |
| | | 8. Reserve transition adjustment | (35,449) | (44,311) | 8,862 |
| | | 9. Accrued lease | - | - | - |
| | | 99. Subtotal | (38,940) | (45,645) | 6,705 |
| | b. | Capital | | | |
| | | 1. Investments | - | - | - |
| | | 2. Real estate | - | - | - |
| | | 3. Other | - | - | - |
| | | 99. Subtotal | - | - | - |
| | c. | DTLs | \$ (38,940) | \$ (45,645) \$ | 6,705 |
| (4) | Net | t deferred tax asset/(liability) | \$ 17,828,765 | \$ 10,304,552 \$ | 7,524,213 |

D. The provision for federal income taxes incurred is different from that which would be obtained by applying the statutory Federal income tax rate to income before income taxes. The significant items causing this difference as of December 31, 2021 are as follows:

| | Amount | Tax Effect | Effective Tax Rate |
|---|-------------------|------------------|-----------------------|
| Income before taxes | \$ 176,970,041 | \$ 37,163,709 | 21.00% |
| Tax-exempt interest | (739,223) | (155,237) | (0.09%) |
| Dividends received deduction | - | - | 0.00% |
| Proration | 184,806 | 38,809 | 0.02% |
| Meals & entertainment, lobbying expenses, etc. | - | - | 0.00% |
| Statutory valuation allowance adjustment Change to nonadmitted assets & deferred tax | - | - | 0.00% |
| true-up | (38,895,938) | (8,168,147) | (4.62%) |
| Other, including prior year true-up | | | 0.00% |
| Total | \$ 137,519,686 | \$ 28,879,134 | 16.32% |
| Federal income taxes incurred | | | |
| [expense/(benefit)] | | \$ 34,839,994 | 19.69% |
| Tax on capital gains/(losses) | | 1,591,211 | 0.90% |
| Change in net deferred income tax [charge/(benefit)] | | (7,552,071) | (4.27%) |
| Total statutory income taxes | | \$ 28,879,134 | 16.32% |

- E. Operating loss and tax credit carry-forwards and protective tax deposits
 - (1) At December 31, 2021, the Company had no net operating loss carry-forwards.

At December 31, 2021, the Company had no capital loss carry-forwards.

At December 31, 2021, the Company had no AMT credit carry-forwards.

(2) The following table demonstrates the income tax expense for 2020 and 2021 that is available for the recoupment in the event of future net losses:

| | Ordinary | Capital | Total |
|-------|---------------------|-----------|------------------|
| 2020 | 59,850,647 | 2,200,822 | 62,051,469 |
| 2021 | 34,842,150 | 1,591,211 | 36,433,361 |
| Total | \$ 94,692,797 \$ | 3,792,033 | \$ 98,484,830 |

- (3) There are no deposits admitted under IRC § 6603.
- F. The Company is included in a consolidated federal income tax return with its parent Company, Humana Inc. The Company has a written agreement, approved by the Company's Board of Directors, which sets forth the manner in which the total combined federal income tax is allocated to each entity which is a party to the consolidation. Pursuant to this agreement, the Company has the enforceable right to be paid for any future net losses it may incur. The Company has no contingent income tax liabilities. The Company has not adjusted gross deferred tax assets due to changes in judgment about the realizability of the related deferred tax asset. The Company has no deposits under Section 6603 of the Internal Revenue Code.

NOTES TO THE FINANCIAL STATEMENTS

HUMANA INC. AND SUBSIDIARIES INCLUDED IN 2021 CONSOLIDATED FEDERAL INCOME TAX RETURN

CALENDAR YEAR ENDED DECEMBER 31, 2021 AFFILIATIONS SCHEDULE

CORPORATE NAME AND EMPLOYER IDENTIFICATION NUMBER THE ADDRESS OF EACH COMPANY IS: P. O. BOX 740026, LOUISVILLE, KY 40201

| CORP. | | EMPLOYER IDENTIFICATION |
|----------|--|--------------------------|
| NO. | CORPORATION NAME | NUMBER |
| 1 | HUMANA INC. | 61-0647538 |
| 2 | 154TH STREET MEDICAL PLAZA, INC. | 65-0851053 |
| 3 | 516-526 WEST MAIN STREET CONDOMINIUM COUNCIL OF CO-OWNERS INC. | |
| 4 | 54TH STREET MEDICAL PLAZA, INC. | 65-0293220 |
| 5 | ABERDEEN HOLDINGS, INC. | 72-2695805 |
| 6 | ABLE HOME HEALTHCARE, INC. | 77-0601595 |
| 7 | ADVANCED ONCOLOGY SERVICES, INC. | 65-0180784 |
| 8 | ALPINE HOME HEALTH CARE, LLC | 36-4473376 |
| 9 | AMERICAN HOMECARE MANAGEMENT CORP. | 11-3306095 |
| 10 | AMERICAN HOSPICE, INC. | 75-2486047 |
| 11 | AMICUS MEDICAL CENTER, LLC | 45-4020797 |
| 12 | AMICUS MEDICAL GROUP, INC. | 27-3974953 |
| 13 | AMICUS MEDICAL SERVICES ORGANIZATION, LLC | 27-1085323 |
| 14 | ARCADIAN HEALTH PLAN, INC. | 20-1001348 |
| 15 | ASIAN AMERICAN HOME CARE, INC. | 94-3247811 |
| 16 | CAC MEDICAL CENTER HOLDINGS, INC. | 30-0117876 |
| 17 | CAC-FLORIDA MEDICAL CENTERS, LLC | 26-0010657 |
| 18 | CARENETWORK, INC. | 39-1514846 |
| 19 | CAREPLUS HEALTH PLANS, INC. | 59-2598550 |
| 20 | CARITEN HEALTH PLAN INC. | 62-1579044 |
| 21 | CENTERWELL CARE SOLUTIONS, INC. (f/k/a PRIMARY CARE MANAGEMENT, INC.) | 85-0858631 |
| 22 | CENTERWELL SENIOR PRIMARY CARE (FL), INC. (f/k/a FAMILY PHYSICIANS OF WINTER PARK, INC.) | 59-3164234 |
| 23 | CENTERWELL SENIOR PRIMARY CARE (KS), P.A. (f/k/a PARTNERS IN PRIMARY CARE (KS), P.A.) | 30-1236218 |
| 24 25 | CENTERWELL SENIOR PRIMARY CARE (MO), P.C. (f/k/a PARTNERS IN PRIMARY CARE (MO), P.C.) CENTERWELL SENIOR PRIMARY CARE (NC), P.C. (f/k/a PARTNERS IN | 85-3676937 82-1926920 |
| 26 | PRIMARY CARE (NC), P.C.) CENTERWELL SENIOR PRIMARY CARE (SC), P.C. (f/k/a PARTNERS IN | 85-3577914 |
| 27 | PRIMARY CARE (SC), P.C.) CENTRAL ARIZONA HOME HEALTH CARE, INC. | 86-0714789 |
| 28 | CH SERVICES GROUP HOLDINGS, INC. | 47-3061031 |
| 29 | CH SERVICES HOLDINGS, INC. | 47-3083265 |
| 30 | CH SERVICES MIDCO HOLDINGS, INC. | 47-3083393 |
| 31 | CHA HMO, INC. | 61-1279717 |
| 32 | CHAPARRAL HOSPICE, INC. | 35-2224605 |
| 33 | CHARLOTTE BUYER, INC. | 82-5266576 |
| 34 | COMPASS HOSPICE, INC. | 27-0001235 |
| 35 | COMPBENEFITS COMPANY | 59-2531815 |
| 36 | COMPBENEFITS CORPORATION | 04-3185995 |
| 37 | COMPBENEFITS DENTAL, INC. | 36-3686002 |
| 38 | COMPBENEFITS DIRECT, INC. | 58-2228851 |
| 39 | COMPBENEFITS INSURANCE COMPANY | 74-2552026 |
| 40 | COMPLEX CLINICAL MANAGEMENT, INC. | 45-3713941 |
| 41 | CONVINA HEALTH MANAGEMENT, LLC | 59-2716023 |
| 42 43 | CONVIVA HEALTH MANAGEMENT, LLC | 46-5329373 |
| | CONVIVA MEDICAL CENTED MANAGEMENT OF TEVAS, D.A. | 46-1225873 |
| 44 45 | CONVIVA MEDICAL CENTER MANAGEMENT OF TEXAS, P.A. CURO HEALTH SERVICES HOLDINGS, INC. | 47-1161014 27-3569032 |
| 45 | CURO TEXAS HOLDINGS, LLC | 46-3096415 |
| 47 | CURO UTAH HOME CARE, INC. | 27-3500910 |
| 48 | CURO UTAH HOSPICE, INC. | 27-3500710 |
| 49 | DENTAL CARE PLUS MANAGEMENT, CORP. | 36-3512545 |
| 50 | DENTICARE, INC. | 76-0039628 |
| 51 | EAGLE RX HOLDCO, INC. | 47-1407967 |
| 52 | EAGLE RX, INC. | 47-1416614 |

NOTES TO THE FINANCIAL STATEMENTS

| 53 | EDGE HEALTH MSO, INC. | 84-2214810 |
|-----|--|------------|
| 54 | EDGE HEALTH MSO, INC. EDGE HEALTH, P.C. | 84-2752906 |
| 55 | EMPHESYS INSURANCE COMPANY | 31-0935772 |
| | | |
| 56 | EMPHESYS, INC. | 61-1237697 |
| 57 | ENCLARA PHARMACIA, INC. | 23-3068914 |
| 58 | FHI GP, INC. | 75-2588220 |
| 59 | FHI HEALTH SYSTEMS, INC. | 75-2588219 |
| 60 | FHI LP, INC. | 88-0335145 |
| 61 | FIRST HOME HEALTH, INC. | 55-0750157 |
| 62 | FOCUS CARE HEALTH RESOURCES, INC. | 75-2784006 |
| 63 | FPG ACQUISITION CORP. | 81-3802918 |
| 64 | FPG ACQUISITION HOLDINGS CORP. | 81-3819187 |
| 65 | FPG HOLDING COMPANY, LLC | 32-0505460 |
| 66 | GBA HOLDING, INC. | 75-2855493 |
| 67 | GENERATIONS HOSPICE SERVICE CORPORATION | 42-1581419 |
| 68 | GENTIVA CERTIFIED HEALTHCARE CORP. | 11-2645333 |
| 69 | GENTIVA HEALTH SERVICES (CERTIFIED), INC. | 11-3454105 |
| 70 | GENTIVA HEALTH SERVICES HOLDING CORP. | 11-3454104 |
| 71 | GENTIVA HEALTH SERVICES, INC. | 36-4335801 |
| 72 | GENTIVA SERVICES OF NEW YORK, INC. | 11-2802024 |
| 73 | GILBERT'S HOME HEALTH AGENCY, INC. | 64-0730826 |
| 74 | GIRLING HEALTH CARE SERVICES OF KNOXVILLE, INC. | 62-1406895 |
| 75 | GIRLING HEALTH CARE, INC. | 74-2115034 |
| 76 | GUIDANTRX, INC. | 39-1789830 |
| 77 | HARRIS, ROTHENBERG INTERNATIONAL INC. | 27-1649291 |
| 78 | HAWKEYE HEALTH SERVICES, INC. | 42-1285486 |
| 79 | HEALTH VALUE MANAGEMENT, INC. | 61-1223418 |
| 80 | HHS HEALTHCARE CORP. | 90-0527683 |
| 81 | HOME HEALTH CARE AFFILIATES OF MISSISSIPPI, INC. | 62-1775256 |
| 82 | HOME HEALTH CARE AFFILIATES, INC. | 74-2737989 |
| 83 | HOME HEALTH OF RURAL TEXAS, INC. | 75-2374091 |
| 84 | HOME HEALTH OF KOKAE TEXAS, INC. HOME HEALTH SERVICES, INC. | 87-0494759 |
| 85 | HOMECARE HOLDINGS, INC. | 65-0837269 |
| | • | |
| 86 | HORIZON HEALTH CARE SERVICES, INC. | 76-0456316 |
| 87 | HOSPICE FAMILY CARE, INC. | 86-0710921 |
| 88 | HOUSE CALL DOCTORS, INC. | 20-3811538 |
| 89 | HUMANA ACTIVE OUTLOOK, INC. | 20-4835394 |
| 90 | HUMANA AT HOME (DALLAS), INC. | 75-2739333 |
| 91 | HUMANA AT HOME (HOUSTON), INC. | 76-0537878 |
| 92 | HUMANA AT HOME (SAN ANTONIO), INC | 01-0766084 |
| 93 | HUMANA AT HOME (TLC), INC. | 75-2600512 |
| 94 | HUMANA AT HOME 1, INC. | 65-0274594 |
| 95 | HUMANA AT HOME, INC. | 13-4036798 |
| 96 | HUMANA BENEFIT PLAN OF ILLINOIS, INC. | 37-1326199 |
| 97 | HUMANA BENEFIT PLAN OF SOUTH CAROLINA, INC. | 84-3226630 |
| 98 | HUMANA BENEFIT PLAN OF TEXAS, INC. | 75-2043865 |
| 99 | HUMANA DENTAL COMPANY | 59-1843760 |
| 100 | HUMANA DIGITAL HEALTH AND ANALYTICS PLATFORM SERVICES, | 80-0072760 |
| | INC. | |
| 101 | HUMANA DIRECT CONTRACTING ENTITY, INC. | 85-3099097 |
| 102 | HUMANA EAP AND WORK-LIFE SERVICES OF CALIFORNIA, INC. | 46-4912173 |
| 103 | HUMANA EMPLOYERS HEALTH PLAN OF GEORGIA, INC. | 58-2209549 |
| 104 | HUMANA GOVERNMENT BUSINESS, INC. | 61-1241225 |
| 105 | HUMANA HEALTH BENEFIT PLAN OF LOUISIANA, INC. | 72-1279235 |
| 106 | HUMANA HEALTH COMPANY OF NEW YORK, INC. | 26-2800286 |
| 107 | HUMANA HEALTH INSURANCE COMPANY OF FLORIDA, INC. | 61-1041514 |
| 108 | HUMANA HEALTH PLAN OF CALIFORNIA, INC. | 26-3473328 |
| 109 | HUMANA HEALTH PLAN OF OHIO, INC. | 31-1154200 |
| 110 | HUMANA HEALTH PLAN OF TEXAS, INC. | 61-0994632 |
| 111 | HUMANA HEALTH PLAN, INC. | 61-1013183 |
| 112 | HUMANA HEALTHCARE RESEARCH, INC. | 42-1575099 |
| 113 | HUMANA HOME ADVANTAGE (TX), P.A. | 81-0789608 |
| 114 | HUMANA INNOVATION ENTERPRISES, INC. | 61-1343791 |
| 115 | HUMANA INSURANCE COMPANY | 39-1263473 |
| 116 | HUMANA INSURANCE COMPANY OF KENTUCKY | 61-1311685 |
| 117 | HUMANA INSURANCE COMPANY OF NEW YORK | 20-2888723 |
| 118 | HUMANA MARKETPOINT, INC. | 61-1343508 |
| 119 | HUMANA MEDICAL PLAN OF MICHIGAN, INC. | 27-3991410 |
| 120 | HUMANA MEDICAL PLAN OF PENNSYLVANIA, INC. | 27-4460531 |
| 121 | HUMANA MEDICAL PLAN OF UTAH, INC. | 20-8411422 |
| | | 0.11122 |

NOTES TO THE FINANCIAL STATEMENTS

| 122 | HUMANA MEDICAL PLAN, INC. | 61-1103898 |
|-----|--|-------------|
| 123 | HUMANA PHARMACY SOLUTIONS, INC. | 45-2254346 |
| 124 | HUMANA PHARMACY, INC. | 61-1316926 |
| 125 | HUMANA REAL ESTATE COMPANY | 20-1724127 |
| 126 | HUMANA REGIONAL HEALTH PLAN, INC. | 20-2036444 |
| | , | |
| 127 | HUMANA WISCONSIN HEALTH ORGANIZATION INSURANCE | 39-1525003 |
| 120 | CORPORATION | 20.051.4200 |
| 128 | HUMANADENTAL INSURANCE COMPANY | 39-0714280 |
| 129 | HUMANADENTAL, INC. | 61-1364005 |
| 130 | HUMCO, INC. | 61-1239538 |
| 131 | HUM-E-FL, INC. | 61-1383567 |
| 132 | INDEPENDENT CARE HEALTH PLAN | 39-1769093 |
| | | |
| 133 | INTEGRACARE HOLDINGS, INC. | 20-8781607 |
| 134 | INTEGRACARE HOME HEALTH SERVICES, INC. | 75-2865632 |
| 135 | INTEGRACARE INTERMEDIATE HOLDINGS, INC. | 20-8781715 |
| 136 | ISIDORA'S HEALTH CARE, INC. | 65-1285069 |
| 137 | KAH DEVELOPMENT 16, INC. | 87-0548601 |
| 138 | KENTUCKY HOMECARE HOLDINGS, INC. | 82-3695166 |
| | | |
| 139 | KENTUCKY HOMECARE PARENT INC. | 82-3986306 |
| 140 | KSOC HOLDINGS, INC. | 80-0766080 |
| 141 | LOVING PEACE HOSPICE, INC. | 47-1818578 |
| 142 | MANAGED CARE INDEMNITY, INC. | 61-1232669 |
| 143 | MED. TECH. SERVICES OF SOUTH FLORIDA, INC. | 65-0277280 |
| 144 | MEDICAL ADVOCATE HEALTHCARE SERVICES CORPORATION | |
| | | 27-2932981 |
| 145 | MEDICAL CARE CONSORTIUM INCORPORATED OF TEXAS | 27-4379634 |
| 146 | MED-TECH SERVICES OF DADE, INC. | 65-1033439 |
| 147 | MED-TECH SERVICES OF PALM BEACH, INC. | 65-0644307 |
| 148 | METCARE OF FLORIDA, INC. | 65-0879131 |
| 149 | METROPOLITAN HEALTH NETWORKS, INC. | 65-0635748 |
| | | |
| 150 | MISSOURI HOME CARE OF ROLLA, INC. | 43-1317147 |
| 151 | NEW CENTURY HOSPICE, INC. | 20-5435710 |
| 152 | NEW YORK HEALTHCARE SERVICES, INC. | 22-2695367 |
| 153 | NURSING CARE-HOME HEALTH AGENCY, INC. | 55-0633030 |
| 154 | ODYSSEY HEALTHCARE HOLDING COMPANY | 75-2925311 |
| | ODYSSEY HEALTHCARE MANAGEMENT, LP | |
| 155 | , | 75-2923658 |
| 156 | ODYSSEY HEALTHCARE OPERATING A, LP | 75-2752908 |
| 157 | ODYSSEY HEALTHCARE, INC. | 43-1723043 |
| 158 | OHS SERVICE CORP. | 22-3690699 |
| 159 | PBM HOLDING COMPANY | 61-1340806 |
| 160 | PBM PLUS MAIL SERVICE PHARMACY, LLC | 20-2373204 |
| | | |
| 161 | PHH ACQUISITION CORP. | 20-5043135 |
| 162 | PHHC ACQUISITION CORP. | 38-3784032 |
| 163 | PHP COMPANIES, INC. | 62-1552091 |
| 164 | PREFERRED HEALTH PARTNERSHIP, INC. | 62-1250945 |
| 165 | QC-MEDI NEW YORK, INC. | 11-2750425 |
| 166 | QUALITY CARE - USA, INC. | 11-2256479 |
| | | |
| 167 | REGENCY HOSPICE OF NORTHWEST FLORIDA, INC. | 26-3437769 |
| 168 | ROHC, L.L.C. | 75-2844854 |
| 169 | SENIOR HOME CARE, INC. | 59-3080333 |
| 170 | SENIORBRIDGE FAMILY COMPANIES (FL), INC. | 65-1096853 |
| 171 | SENIORBRIDGE FAMILY COMPANIES (NY), INC. | 36-4484443 |
| | | |
| 172 | SHC HOLDING, INC. | 42-1699530 |
| 173 | SOUTHERN NEVADA HOME HEALTH CARE, INC. | 87-0494757 |
| 174 | SOUTHERNCARE HOLDINGS, INC. | 48-1288826 |
| 175 | SOUTHERNCARE, INC. | 16-1645414 |
| 176 | SUN BROOK HOME CARE, LLC | 06-1810593 |
| 177 | SYNERGY HOME CARE-ACADIANA REGION, INC. | 72-1487473 |
| | | 20-1376846 |
| 178 | SYNERGY HOME CARE-CAPITOL REGION, INC. | |
| 179 | SYNERGY HOME CARE-CENTRAL REGION, INC. | 36-4516940 |
| 180 | SYNERGY HOME CARE-NORTHEASTERN REGION, INC. | 72-1178497 |
| 181 | SYNERGY HOME CARE-NORTHSHORE REGION, INC. | 72-1223659 |
| 182 | SYNERGY HOME CARE-NORTHWESTERN REGION, INC. | 72-1431394 |
| 183 | SYNERGY HOME CARE-SOUTHEASTERN REGION, INC. | 72-1429305 |
| | · | |
| 184 | SYNERGY, INC. | 93-3419676 |
| 185 | TEXAS DENTAL PLANS, INC. | 74-2352809 |
| 186 | THE AMERICAN HEARTLAND HOSPICE CORP. | 43-1697602 |
| 187 | THE DENTAL CONCERN, INC. | 52-1157181 |
| 188 | THE HOME OPTION, LLC | 26-2527353 |
| 189 | THE HOME TEAM OF KANSAS LLC | 74-3052911 |
| | | |
| 190 | TRANSCEND COMMUNITY PHYSICIAN NETWORK (AR), P.A. | 47-2770181 |
| | | |

NOTES TO THE FINANCIAL STATEMENTS

| 191 | TRANSCEND COMMUNITY PHYSICIAN NETWORK (KS), P.A. | 47-2111323 |
|-----|--|------------|
| 192 | TRANSCEND COMMUNITY PHYSICIAN NETWORK, P.C. | 47-2750105 |
| 193 | US HOUSE CALL PRACTITIONERS, INC. | 47-2064816 |
| 194 | VAN WINKLE HOME HEALTH CARE, INC. | 62-1669388 |
| 195 | VOYAGER HOME HEALTH, INC. | 26-1501792 |
| 196 | VOYAGER HOSPICECARE, INC. | 20-1173787 |

G. The Company does not have any tax loss contingencies for which it is reasonably possible that the total liability will significantly increase within twelve months of the reporting date.

10. Information Concerning Parent, Subsidiaries and Affiliates

A.-B. The Company has several management contracts with Humana Inc. and other related parties whereby the Company is provided with medical and executive management, information systems, claims processing, billing and enrollment, and telemarketing and other services as required by the Company. Management fees charged to operations for the years ended December 31, 2021 and 2020 were \$541,215,335 and \$554,467,058, respectively. As a part of this agreement, Humana Inc. makes cash disbursements on behalf of the Company which includes, but is not limited to, medical related items, general and administrative expenses, commissions and payroll. The Company continues to be primarily liable for any outstanding payments made on behalf of the Company, should Humana Inc. not be able to fulfill its obligations.

In the ordinary course of business, the Company also directly contracts with related parties to provide services that are routine in nature to its members. The administrative services, access fees, and cost of care services provided are determined within each individual agreement. The following table identifies the amount for the administrative services, access fees, and cost of care services provided by related parties for the years ended December 31, 2021 and 2020, which meet the disclosure requirements pursuant to SSAP No. 25, *Affiliate and Other Related Parties* (SSAP No. 25):

| | <u>2021</u> | | <u>2020</u> |
|-------------------------------------|-------------------|----|-------------|
| SeniorBridge and Humana At Home | \$ 48,486,145 | \$ | 44,436,372 |
| CenterWell Senior Primary Care Inc. | 60,973,801 | | 36,260,456 |
| Kindred | 31,813,023 | | - |
| Total | \$ 141,272,969 | \$ | 80,696,828 |

In addition to the related parties above, the Company also has a contracted relationship with Humana Pharmacy Solutions, Inc. (HPS). HPS is responsible for designing pharmacy benefits, including defining member co-share responsibilities, determining formulary listings, contracting with retail pharmacies, confirming member eligibility, reviewing drug utilization, and processing claims for Humana entities. HPS has various contracts with pharmacy manufacturers to provide the Company with purchase discounts and volume rebates on certain prescription drugs utilized by its members. The Company has an agreement with HPS to collect pharmacy rebates on its behalf and remit them to the Company on a monthly basis. The Company had \$1,851,081,081 and \$1,504,533,053 of administrative service and prescription costs in 2021 and 2020, respectively, with HPS. The prescription costs included in fees paid to HPS are gross of the pharmacy rebates that the Company receives, see Footnote 28, and also includes payments for Medicare Part D claims that CMS reimburses the Company for through the Coverage Gap, Low Income and Reinsurance subsidies.

Included in the payments to HPS are also costs incurred from Humana Pharmacy, Inc. Humana Pharmacy, Inc. provides covered members with prescription services through use of the mail order as well as brick and mortar locations. These services are limited to maintenance medication prescription drug and allied services and supplies normally provided to the general public in the ordinary course of pharmacy business. The Company had \$594,347,603 and \$504,044,249 of prescription costs in 2021 and 2020, respectively, with Humana Pharmacy, Inc.

Total dividends of \$75,000,000 were paid to Humana Inc. on April 15, 2021. The Washington Office of Insurance was notified prior to the payment of these dividends.

C. (1) Detail of Material Related Party Transactions

Not Applicable.

(2) Detail of Material Related Party Transactions Involving Services

Not Applicable.

(3) Detail of Material Related Party Transactions Exchange of Assets and Liabilities

Not Applicable.

(4) Detail of Amounts Owed To/From a Related Party

Not Applicable.

- D. At December 31, 2021, the Company reported \$30,026,184 due to Humana Inc. Amounts due to or from parent are generally settled within 90 days.
- E. Not Applicable.
- F. Not Applicable.
- G. All outstanding shares of the Company are owned by the Parent Company.
- H. Not Applicable.
- I. Not Applicable.

NOTES TO THE FINANCIAL STATEMENTS

- J. Not Applicable.
- K. Not Applicable.
- L. Not Applicable.
- M. All SCA Investments

Not Applicable.

N. Investment in Insurance SCA

Not Applicable.

O. SCA Loss Tracking

Not Applicable.

11. <u>Debt</u>

A. Debt Including Capital Notes

The Company has no debentures outstanding.

The Company has no capital notes outstanding.

The Company does not have any reverse repurchase agreements.

B. Federal Home Loan Bank (FHLB) Agreements

The Company does not have any FHLB agreements.

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

A.-D. Defined Benefit Plans

Not Applicable.

E. Defined Contribution Plans

Not Applicable.

F. Multiemployer Plans

Not Applicable.

G. Consolidated/Holding Company Plans

The Company employees are eligible to participate in the Humana Retirement and Savings Plan ("the Plan"), a defined contribution plan, sponsored by Humana Inc. The Plan maintains two accounts, the Savings Account and the Retirement Account.

Humana Inc.'s total contributions paid to the Savings and Retirement accounts of the Humana Retirement Savings Plan were \$257,039,906 and \$233,856,665 for the years ended December 31, 2021 and 2020, respectively. Of these contributions, the Company contributed \$5,505 and \$8,011 during 2021 and 2020, respectively. As of December 31, 2021 and 2020, the fair market value of the Humana Retirement Savings Plan's assets was \$7,333,284,462 and \$6,280,051,531, respectively.

H. Postemployment Benefits and Compensated Absences

Not Applicable.

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

Not Applicable.

13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations

- A. The Company has \$16.667 par value common stock with 60,000 shares authorized and 60,000 shares issued and 60,000 outstanding. All shares are common stock shares.
- B. The Company has no preferred stock outstanding.
- C.-E. Dividends and returns of capital to shareholders are noncumulative and are paid as determined by the Board of Directors. In accordance with the Office statutes, the maximum amount which can be paid by the Company to shareholders without prior approval by the Office is the lesser of 10% of total surplus, or the greater of net operating gain for the calendar year preceding the dividend or for the 3 calendar years preceding the dividend less dividends paid for the most recent 2 of those calendar years. All ordinary dividends are limited to available and accumulated surplus funds. Based on these restrictions, the Company could have paid a maximum dividend or return of capital to shareholders of approximately \$87,900,000 in 2021 without prior regulatory approval.

NOTES TO THE FINANCIAL STATEMENTS

Within the limitations above, there are no restrictions placed on the portion of Company profits that may be paid as ordinary dividends to stockholders.

Dividends or returns of capital paid by the Company are listed below.

| | | Dividend or Ret | | |
|----------|--------------------|------------------|----------------------|----------------|
| | | Ordinary | Extraordinary | Date Paid |
| Dividend | | \$ 75,000,000 | \$ - | April 15, 2021 |
| | Total paid in 2021 | \$ 75,000,000 | \$ - | |

- F. There were no restrictions placed on the Company's surplus, including for whom the surplus is being held.
- G. Not Applicable.
- H. Not Applicable.
- Not Applicable.
- J. The portion of unassigned funds (surplus) represented or reduced by cumulative unrealized gains and losses is \$(288,935).
- K. Not Applicable.
- L. Not Applicable.
- M. Not Applicable.

14. Liabilities, Contingencies and Assessments

A. Contingent Commitments

Not Applicable.

B. Assessments

Not Applicable.

C. Gain Contingencies

Not Applicable.

D. Claims related extra contractual obligation and bad faith losses stemming from lawsuits

Not Applicable.

E. Joint and Several Liabilities

Not Applicable.

F. All Other Contingencies

During the ordinary course of business, the Company is subject to pending and threatened legal actions. Management of the Company does not believe that any of these actions will have a material adverse effect on the Company's surplus, results of operations or cash flows. However, the likelihood or outcome of current or future legal proceedings cannot be accurately predicted, and they could adversely affect the Company's surplus, results of operations and cash flows.

The Company is not aware of any other material contingent liabilities as of December 31, 2021.

15. Leases

Not Applicable.

 Information about Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk

The Company has no investment in Financial Instruments with Off-Balance Sheet Risk or Concentrations of Credit Risk.

- 17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities
 - A. Transfers of Receivables Reported as Sales

Not Applicable.

B. Transfer and Servicing of Financial Assets

Not Applicable.

C. Wash Sales

Not Applicable.

NOTES TO THE FINANCIAL STATEMENTS

- 18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans
 - A. ASO Plans

Not Applicable.

B. ASC Plans

Not Applicable.

- C. Medicare or Other Similarly Structured Cost Based Reimbursement Contract
 - (1) The Company records no revenue explicitly attributable to the cost share and reinsurance components of its Medicare or other similarly structured cost based reimbursement contracts.
 - (2) As of December 31, 2021, the Company has recorded a receivable from CMS of \$49,985,435 related to the cost share and reinsurance components of administered Medicare products. The Company does not have any receivables greater than 10% of the Company's accounts receivable from uninsured accident and health plans or \$10,000.
 - (3) As no revenue is recorded in connection with the cost share and reinsurance components of the Company's Medicare or other similarly structured cost based reimbursement contracts, the Company has recorded no allowances and reserves for adjustment of recorded revenues and receivables.
 - (4) The Company has made no adjustment to revenue resulting from audit of receivables related to revenues recorded in the prior period.
- 19. <u>Direct Premium Written/Produced by Managing General Agents/Third Party Administrators</u>

Not Applicable.

20. Fair Value Measurements

A. (1) The fair value of financial assets at December 31, 2021 were as follows:

| | | | | | Net Asset | |
|---------------------------------|----|--------|------------------|---------|-------------|------------------|
| | Le | evel 1 | Level 2 | Level 3 | Value (NAV) | Total |
| a. Assets at fair value | | | | | | |
| Bonds | | | | | | |
| U.S. governments | \$ | - | \$ - | \$ - | \$ - | \$ - |
| Tax-exempt municipal | | - | - | - | - | - |
| Residential mortgage-backed | | - | - | - | - | - |
| Corporate debt securities | | - | 23,687,647 | - | - | 23,687,647 |
| Total bonds | | - | 23,687,647 | - | - | 23,687,647 |
| Total assets at fair value/NAV | \$ | - | \$ 23,687,647 | \$ - | \$ - | \$ 23,687,647 |
| b. Liabilities at fair value | \$ | - | \$ - | \$ - | \$ - | \$ |
| Total liabilities at fair value | \$ | - | \$ - | \$ - | \$ - | \$ - |

The Company reports transfers between Level 1 and Level 2 of the fair value hierarchy levels at the end of the reporting period. There were no transfers between Level 1 and Level 2 of the fair value hierarchy between December 31, 2020 and December 31, 2021.

(2) Fair Value Measurements in (Level 3) of the Fair Value Hierarchy

Not Applicable.

- (3) The Company reports transfers into or out of Level 3 of the fair value hierarchy levels at the end of the reporting period. There were no transfers into or out of Level 3 of the fair value hierarchy levels between December 31, 2020 and December 31, 2021.
- (4) Fair value of actively traded debt securities are based on quoted market prices. Fair value of other debt securities are based on quoted market prices of identical or similar securities or based on observable inputs like interest rates generally using a market valuation approach, or, less frequently, an income valuation approach and are generally classified as Level 2. The Company generally obtains one quoted price for each security from a third party pricing service. These prices are generally derived from recently reported trades for identical or similar securities, including adjustments through the reporting date based upon observable market information. When quoted prices are not available, the third party pricing service may use quoted market prices of comparable securities or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include benchmark yields, reported trades, credit spreads, broker quotes, default rates and prepayment speeds. The Company is responsible for the determination of fair value and as such, the Company performs analysis on the prices received from the third party pricing service to determine whether the prices are reasonable estimates of fair value. The Company's analysis includes a review of monthly price fluctuations as well as a quarterly comparison of the prices received from the pricing service to prices reported by the Company's third party investment advisor. Based on the Company's internal price verification procedures and review of fair value methodology documentation provided by the third party pricing service, there were no material adjustments to the prices obtained from the third party pricing service during the year ended December 31, 2021.
- (5) Derivative Fair Values

Not Applicable.

NOTES TO THE FINANCIAL STATEMENTS

B. Other Fair Value Disclosures

Not Applicable.

C. Fair Values for All Financial Instruments by Levels 1, 2 and 3

| Type of Financial | | | | | | | | | Net Asset Value | | Not Practicable |
|-------------------|--------|-----------------|----|----------------|-------------------|---------------------|---------|---|-----------------|---|------------------|
| Instrument | Aggreg | gate Fair Value | Ac | lmitted Assets | Level 1 | Level 2 | Level 3 | | (NAV) | | (Carrying Value) |
| Bonds, short- | | | | | | | | | | | |
| term | | | | | | | | | | | |
| investments and | | | | | | | | | | | |
| cash equivalents | \$ | 1,393,745,525 | \$ | 1,393,050,556 | \$ 107,533,343 | \$ 1,286,212,182 | \$ | - | \$ | - | \$ |

D. Financial Instruments for which Not Practicable to Estimate Fair Values

Not Applicable.

21. Other Items

A. Extraordinary Items

The emergence and spread of the novel coronavirus, or COVID-19, has impacted the Company's business. During periods of increased incidences of COVID-19, there was a reduction in non-COVID-19 hospital admissions and lower overall healthcare system consumption that decreased utilization. Likewise COVID-19 treatment and testing costs increased utilization. The significant disruption in utilization during 2020 also impacted the Company's ability to implement clinical initiatives to manage health care costs and chronic conditions of its members, and appropriately document their risk profiles, and, as such, affecting 2021 revenue under the risk adjustment payment model for Medicare Advantage plans. Finally, changes in utilization patterns and actions taken in 2020 and 2021 as a result of the COVID-19 pandemic, including the suspension of certain financial recovery programs for a period of time and shifting the timing of claim payments and provider capitation surplus payments, impacted claim reserve development and operating cash flows for 2020 and 2021.

B. Troubled Debt Restructuring: Debtors

Not Applicable.

C. Other Disclosures and Unusual Items

Not Applicable.

D. Business Interruption Insurance Recoveries

Not Applicable.

E. State Transferable and Non-transferable Tax Credits

Not Applicable.

- F. Subprime Mortgage Related Risk Exposure
 - (1) The Company consults with its external investment managers to assess its subprime mortgage related risk exposure. Certain characteristics are utilized to determine if a mortgage-backed security has subprime exposure. The main characteristics reviewed when determining this are the collateral and structure of the security, the loan purpose, loan documentation, occupancy, geographical location, loan size and type. Subprime mortgage borrowers typically have lower credit scores, lower loan balances and higher loan-to-values than other conforming loans. Management's practices include reviewing quantitative and qualitative credit models that analyze loan-level collateral composition, historical underwriter performance trends, the impact of macroeconomic factors, and issuer risks; as well as reviewing the estimation of security cash flows and monthly model calibrations.
 - (2) Direct exposure through investments in sub-prime mortgage loans.

The Company has no direct exposure through investment to sub-prime mortgage loans.

- (3) Direct exposure through other investments:
 - a. Residential mortgage backed securities No substantial exposure noted.
 - b. Commercial mortgage backed securities No substantial exposure noted.
 - c. Collateralized debt obligations No substantial exposure noted.
 - d. Structured securities No substantial exposure noted.
 - e. Equity investment in SCAs No substantial exposure noted.
 - f. Other assets No substantial exposure noted.
 g. Total No substantial exposure noted.
- (4) Underwriting exposure to sub-prime mortgage risk through Mortgage Guaranty coverage, Financial Guaranty coverage, Directors and Officers liability coverage, or Errors and Omissions liability coverage.

The Company does not have sub-prime mortgage risk.

Classification of mortgage related securities is primarily based on information from outside data services, including rating agency actions. When considering our exposure, the Company evaluated the percentage of full documentation loans, percent of owner occupied properties, FICO scores, average margin for ARM loans, percent of loans with prepayment penalties, the existence of non-traditional underwriting standards, among other factors.

NOTES TO THE FINANCIAL STATEMENTS

G. Retained Assets

Not Applicable.

H. Insurance Linked Securities

Not Applicable.

22. Events Subsequent

The Company is not aware of any events or transactions occurring subsequent to the close of the books for this statement which may have a material effect on its financial condition. Subsequent events have been considered through February 22, 2022 for the Statutory Statement issued on February 22, 2022.

23. Reinsurance

A. Ceded Reinsurance Report

Section 1 - General Interrogatories

(1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10.0 percent or controlled, either directly or indirectly, by the company or by any representative, officer, trustee, or director of the company?

Yes () No (X)

(2) Have any policies issued by the company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10.0 percent or controlled directly or indirectly by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?

Yes () No (X)

Section 2 - Ceded Reinsurance Report - Part A

(1) Does the company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credits?

Yes() No(X)

(2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes () No (X)

Section 3 - Ceded Reinsurance Report - Part B

- (1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the company may consider the current or anticipated experience of the business reinsured in making this estimate. \$0
- (2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the company as of the effective date of the agreement?

Yes () No (X)

B. Uncollectible Reinsurance

Not Applicable.

C. Commutation of Ceded Reinsurance

Not Applicable.

D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation

Not Applicable.

24. Retrospectively Rated Contracts and Contracts Subject to Redetermination

- A. The Company estimates accrued retrospective premium adjustments for its Medicare business through a mathematical approach using an algorithm based upon settlement procedures defined by contracts with CMS.
- B. The Company records accrued retrospective premium as an adjustment to earned premiums.
- C. The amount of net premiums written by the Company at December 31, 2021 that are subject to retrospective rating features was \$6,368,144,084, or 100.00% of the total net premiums written. No other net premiums written by the Company are subject to retrospective rating features.

STATEMENT AS OF December 31, 2021 OF Arcadian Health Plan, Inc.

NOTES TO THE FINANCIAL STATEMENTS

D. Medical loss ratio rebates required pursuant to the Public Health Service Act

Not Applicable.

E. Risk Sharing Provisions of the Affordable Care Act

Not Applicable.

25. Change in Incurred Claims and Claim Adjustment Expenses

Benefits and loss adjustment expenses payable, net of health care receivables, as of December 31, 2020, were \$565,819,850. As of December 31, 2021, \$415,682,480 has been paid for incurred claims and claim adjustment expenses attributable to insured events of prior years. Reserves remaining for prior years are now \$70,528,086 as a result of re-estimation of unpaid claims and claim adjustment expenses. Therefore, there has been a \$79,609,284 favorable prior-year development since December 31, 2020. The decrease is generally the result of ongoing analysis of recent loss development trends. Original estimates are increased or decreased as additional information becomes known regarding individual claims. Included in this decrease, the Company experienced \$79,609,284 of favorable prior year claim development on retrospectively rated policies. However, the business to which it relates is subject to premium adjustments.

26. <u>Intercompany Pooling Arrangements</u>

Not Applicable.

27. Structured Settlements

The Company has no structured settlements.

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

| | Est | imate Pharmacy | Ph | armacy Rebates | | | | tual Rebates | Actu | al Rebates |
|------------|-----|------------------|----|----------------|---------|--------------|-------|---------------|------|------------|
| | Reb | ates as Reported | | as Billed or | Actua | l Rebates | Recei | ved Within 91 | Rece | ived More |
| | | on Financial | | Otherwise | Receiv | ed Within | to | 180 Days of | than | 181 Days |
| Quarter | | Statements | | Confirmed | 90 Days | s of Billing | | Billing | afte | r Billing |
| 12/31/2021 | \$ | 133,869,323 | \$ | 133,869,323 | \$ | - | \$ | - | \$ | - |
| 9/30/2021 | | 139,264,551 | | 138,049,879 | 13 | 35,807,578 | | - | | - |
| 6/30/2021 | | 165,379,681 | | 168,272,180 | 16 | 57,349,477 | | - | | - |
| 3/31/2021 | | 128,534,860 | | 149,972,001 | 14 | 19,729,457 | | - | | 240,697 |
| | | | | | | | | | | |
| 12/31/2020 | | 89,378,981 | | 89,378,981 | 8 | 39,280,479 | | - | | 65,466 |
| 9/30/2020 | | 120,547,639 | | 120,547,639 | 11 | 19,638,771 | | 837,933 | | 70,935 |
| 6/30/2020 | | 134,630,331 | | 134,630,331 | 13 | 33,427,752 | | 1,119,304 | | 83,275 |
| 3/31/2020 | | 98,641,596 | | 98,641,596 | ò | 96,236,730 | | 2,404,866 | | - |
| | | | | | | | | | | |
| 12/31/2019 | | 73,283,351 | | 73,283,351 | 7 | 72,896,071 | | - | | 387,280 |
| 9/30/2019 | | 81,082,048 | | 81,082,048 | 8 | 30,521,374 | | 168,994 | | 391,680 |
| 6/30/2019 | | 119,518,755 | | 119,518,755 | 1 1 | 18,016,591 | | 388,230 | | 1,113,934 |
| 3/31/2019 | | 78,040,458 | | 78,040,458 | 7 | 77,296,766 | | - | | 743,692 |

B. Risk Sharing Receivables

Not Applicable.

29. Participating Policies

The Company has no participating policies.

30. <u>Premium Deficiency Reserves</u>

Not Applicable.

31. Anticipated Salvage and Subrogation

Not Applicable.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES GENERAL

| 1.1 | Is the reporting entity a member of an Insurance Holding Company System is an insurer? | | | /es [X |] No [|] |
|-----|--|--|-----------|---------|--------|-----|
| 1.2 | If yes, did the reporting entity register and file with its domiciliary State Insur such regulatory official of the state of domicile of the principal insurer in the providing disclosure substantially similar to the standards adopted by the Naits Model Insurance Holding Company System Regulatory Act and model resubject to standards and disclosure requirements substantially similar to the | Holding Company System, a registration statement ational Association of Insurance Commissioners (NAIC) in equilations pertaining thereto, or is the reporting entity | Yes [X] | No [|] N/A | .[] |
| 1.3 | State Regulating? | | | Washing | gton | |
| 1.4 | Is the reporting entity publicly traded or a member of a publicly traded group | 9? | ١ | /es [X |] No [|] |
| 1.5 | If the response to 1.4 is yes, provide the CIK (Central Index Key) code issue | ed by the SEC for the entity/group. | | 0000049 | 9071 | |
| 2.1 | Has any change been made during the year of this statement in the charter reporting entity? | | | /es [|] No [| Х] |
| 2.2 | If yes, date of change: | | | | | |
| 3.1 | State as of what date the latest financial examination of the reporting entity | was made or is being made. | | 12/31/2 | 2020 | |
| 3.2 | State the as of date that the latest financial examination report became ava entity. This date should be the date of the examined balance sheet and not | | | 03/31/2 | 2019 | |
| 3.3 | State as of what date the latest financial examination report became availat domicile or the reporting entity. This is the release date or completion date examination (balance sheet date). | of the examination report and not the date of the | | 12/12/2 | 2019 | |
| 3.4 | By what department or departments? Wisconsin Office of the Commissioner of Insurance and 12 other states in a | a coordinated audit | | | | |
| 3.5 | Have all financial statement adjustments within the latest financial examinal statement filed with Departments? | | Yes [X] | No [|] N/A | [] |
| 3.6 | Have all of the recommendations within the latest financial examination rep | ort been complied with? | Yes [X] | No [|] N/A | [] |
| 4.1 | | of the reporting entity), receive credit or commissions for or control of the reporting entity), receive credit or commissions for or control of the reporting entity or an afficient or an af | | |] No [| |
| | premiums) of: | new business? | | es [|] No [| X 1 |
| | | ? | | - |] No [| _ |
| 5.1 | Has the reporting entity been a party to a merger or consolidation during the If yes, complete and file the merger history data file with the NAIC. | e period covered by this statement? | \ | ſes [|] No [| Х] |
| 5.2 | If yes, provide the name of the entity, NAIC Company Code, and state of do ceased to exist as a result of the merger or consolidation. | | as | | | |
| | 1 Name of Entity | NAIC Company Code State of Domicile | | | | |
| 6.1 | Has the reporting entity had any Certificates of Authority, licenses or registratevoked by any governmental entity during the reporting period? | ations (including corporate registration, if applicable) suspend | | Yes [|] No [| Х] |
| 6.2 | If yes, give full information: | | | | | |
| 7.1 | Does any foreign (non-United States) person or entity directly or indirectly or | ontrol 10% or more of the reporting entity? | \ | /es [|] No [| Х] |
| 7.2 | If yes, 7.21 State the percentage of foreign control; | | | 0 | .0 | % |
| | 7.22 State the nationality(s) of the foreign person(s) or entity(s) or if the enti attorney-in-fact; and identify the type of entity(s) (e.g., individual, corporate) | | | | | |
| | 1 Nationality | 2 Type of Entity | | | | |
| | | | | | | |

| 8.1 8.2 | Is the company a subsidiary of a depository institution holding compan If the response to 8.1 is yes, please identify the name of the DIHC. Not Applicable. | | | | | Yes [|] | No [X |] |
|--------------|---|---|----------------------|------------------------|---------|---------|----|---------|----|
| 8.3 | Is the company affiliated with one or more banks, thrifts or securities fi | | | | | Vac [| 1 | No [X | 1 |
| 8.4 | If response to 8.3 is yes, please provide below the names and location regulatory services agency [i.e. the Federal Reserve Board (FRB), the Insurance Corporation (FDIC) and the Securities Exchange Commission | n (city and state of the main office) of any affiliates n Office of the Comptroller of the Currency (OCC), the | egulated ne Feder | d by a fed ral Depo | deral | 103 [| J | NO [X | 1 |
| | 1 | 2 | 3 | 4 | 5 | 6 | 1 | | |
| | Affiliate Name | Location (City, State) | FRB | occ | FDIC | SEC | | | |
| 8.5 | Is the reporting entity a depository institution holding company with sig | <u> </u> | ard of Co | | of | | | | |
| | Federal Reserve System or a subsidiary of the reporting entity? | | | | | Yes [|] | No [X |] |
| 8.6 | Federal Reserve Board's capital rule? | | | \ | /es [|] No [| Х] | N/A [|] |
| 9. | What is the name and address of the independent certified public according | | | | | | | | |
| | PricewaterhouseCoopers LLC, 500 West Main Street, Suite 1800, Lo | | | | | | | | |
| 10.1 | Has the insurer been granted any exemptions to the prohibited non-au requirements as allowed in Section 7H of the Annual Financial Reportile aw or regulation? | ing Model Regulation (Model Audit Rule), or substa | ntially si | milar sta | ite | Yes [|] | No [X |] |
| 10.2 | If the response to 10.1 is yes, provide information related to this exemp | | | | | | | - | |
| 10.3 10.4 | Has the insurer been granted any exemptions related to the other requallowed for in Section 18A of the Model Regulation, or substantially sir If the response to 10.3 is yes, provide information related to this exemption | uirements of the Annual Financial Reporting Model milar state law or regulation? | Regulati | on as | | Yes [|] | No [X |] |
| | | | | | | | | | |
| 10.5 10.6 | Has the reporting entity established an Audit Committee in compliance If the response to 10.5 is no or n/a, please explain | | | | /es [X |] No [|] | N/A [|] |
| 11. | | orting entity or actuary/consultant associated with ar fication? | n actuari | al consu | Ū | | | | |
| 12.1 | Does the reporting entity own any securities of a real estate holding co | ompany or otherwise hold real estate indirectly? | | | | Yes [|] | No [X |] |
| | 12.11 Name of real e | estate holding company | | | | _ | - | | |
| | 12.12 Number of par | rcels involved | | | | 0 | | | |
| | 12.13 Total book/adj | justed carrying value | | | | § | | | 0 |
| 12.2 | If, yes provide explanation: | | | | | | | | |
| 13. | FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITI | IES ONLY: | | | | | | | |
| 13.1 | What changes have been made during the year in the United States m Not Applicable. | | | | | | | | |
| 13.2 | | , - | | | | Yes [|] | No [|] |
| 13.3 | Have there been any changes made to any of the trust indentures duri | | | | | Yes [|] | No [|] |
| 13.4 | If answer to (13.3) is yes, has the domiciliary or entry state approved the | | | | |] No [|] | N/A [| Χ] |
| 14.1 | Are the senior officers (principal executive officer, principal financial of similar functions) of the reporting entity subject to a code of ethics, whi a. Honest and ethical conduct, including the ethical handling of actual relationships; | ich includes the following standards? or apparent conflicts of interest between personal a | ind profe | | | Yes [X |] | No [|] |
| | b. Full, fair, accurate, timely and understandable disclosure in the period c. Compliance with applicable governmental laws, rules and regulation | | ity; | | | | | | |
| | d. The prompt internal reporting of violations to an appropriate person | or persons identified in the code; and | | | | | | | |
| | e. Accountability for adherence to the code. | | | | | | | | |
| 14.11 | If the response to 14.1 is No, please explain: | | | | | | | | |
| 14.2 | Has the code of ethics for senior managers been amended? | | | | | Yes [X |] | No [|] |
| 14.21 | If the response to 14.2 is yes, provide information related to amendme | | | | | - | | - | |
| | Ethics Every Day was amended in June 2021 to update content based | | | | | | | | |
| 14.3 | necessary and perform general document maintenance | | | | | Voc. I | 1 | No I v | 1 |
| | If the response to 14.3 is yes, provide the nature of any waiver(s). | poonica onicera: | | | | Yes [| 1 | IAO [V | 1 |
| . 1.01 | if the response to 14.5 is yes, provide the nature of any waiver(s). | | | | | | | | |

| If the response to 15.1 is yes, indicate the American Bankers Association (ABA) Routing Number and the name of the issuing or confirming bank of the Letter of Credit and describe the circumstances in which the Letter of Credit is triggered. | | | | | |
|--|---|--|--|-------------|----|
| 1 American Bankers Association (ABA) Routing | 2 | | 3 | 4 | |
| Number | Issuing or Confirming Bank Name | | Can Trigger the Letter of Credit | Amount | |
| | | | | | |
| I. die een een een een een een een een een e | | D OF DIRECTORS | the state of the s | | |
| | or sale of all investments of the reporting entity passed | | | Yes [X] I | No |
| | ng entity keep a complete permanent record of the produced in | | | Yes [X] I | No |
| | g entity an established procedure for disclosure to its brofficers, directors, trustees or responsible employees to | | | Yes [X] | No |
| | | FINANCIAL | | | |
| | ent been prepared using a basis of accounting other the ciples)? | an Statutory Accounting Principl | | Yes [] | No |
| | aned during the year (inclusive of Separate Accounts, e | exclusive of policy loans): 20. | 11 To directors or other officers | \$ | |
| | | | 12 To stockholders not officers 13 Trustees, supreme or grand (Fraternal Only) | | |
| Total amount of | loans outstanding at the end of year (inclusive of Sepa | rate Accounts exclusive of | (Fraternal Only) | \$ | |
| policy loans): | iodino odiodanamig at ino ona or your (moderno or oopa | 20.2 | 21 To directors or other officers | | |
| | | | 22 To stockholders not officers 23 Trustees, supreme or grand (Fraternal Only) | | |
| Were any assets | s reported in this statement subject to a contractual obli reported in the statement? | gation to transfer to another par | tv without the liability for such | | |
| | amount thereof at December 31 of the current year: | | 21 Rented from others | | |
| | | 21.3 | 22 Borrowed from others | \$ | |
| | | 21.3 | 23 Leased from others | \$ | , |
| | | 21.3 | 24 Other | \$ | |
| Does this statem | nent include payments for assessments as described in | the Annual Statement Instructi | ons other than guaranty fund or | | |
| guaranty association of the second se | ation assessments? | 22.21 / | Amount paid as losses or risk adjustment | Yes [] I | No |
| | | 22.22 | Amount paid as expenses | \$ | |
| | | 22.23 (| Other amounts paid | \$ | |
| Does the reporti | ng entity report any amounts due from parent, subsidia ny amounts receivable from parent included in the Pag | ries or affiliates on Page 2 of thi | s statement? | Yes [] I | No |
| Does the insurer | r utilize third parties to pay agent commissions in which | the amounts advanced by the t | hird parties are not settled in full within | | |
| | o 24.1 is yes, identify the third-party that pays the agen | | | | |
| | | Is the Third-Party Agent a Related Party | | | |
| | Name of Third-Party | (Yes/No) | | | |
| | | · | | | |

| 25.02 | If no, give full and complete information relating thereto | | | | |
|---|---|--|---|---|----------------------------------|
| 25.03 | whether collateral is carried on or off-balance sheet. (an alternative | rogram including value for collateral and amount of loaned securities, and ative is to reference Note 17 where this information is also provided) | - | | |
| 25.04 | For the reporting entity's securities lending program, report and Instructions. | ount of collateral for conforming programs as outlined in the Risk-Based Capital | I \$ | | 0 |
| 25.05 | For the reporting entity's securities lending program, report amount | ount of collateral for other programs. | \$ | | 0 |
| 25.06 | Does your securities lending program require 102% (domestic outset of the contract? | securities) and 105% (foreign securities) from the counterparty at the | [] No [|]] N/ | 'A [X] |
| 25.07 | Does the reporting entity non-admit when the collateral receive | ed from the counterparty falls below 100%? | [] No [|] N/ | Ά [Χ] |
| 25.08 | Does the reporting entity or the reporting entity's securities len conduct securities lending? | nding agent utilize the Master Securities lending Agreement (MSLA) to Yes [| [] No [| [] N/ | 'A [X] |
| 25.09 | For the reporting entity's securities lending program state the a | amount of the following as of December 31 of the current year: | | | |
| | 25.092 Total book adjusted/carrying value of re | assets reported on Schedule DL, Parts 1 and 2einvested collateral assets reported on Schedule DL, Parts 1 and 2 | \$ | | 0 |
| 26.1 | control of the reporting entity, or has the reporting entity sold or | entity owned at December 31 of the current year not exclusively under the r transferred any assets subject to a put option contract that is currently in 5.03). | Yes [| X] No | [] |
| 26.2 | If yes, state the amount thereof at December 31 of the current | year: 26.21 Subject to repurchase agreements | \$\$\$\$\$\$\$\$ | 11, | 0 0 0 0 0 508,922 |
| | | 26.31 Pledged as collateral to FHLB - including assets backing funding agreements | \$ | | 0 |
| | | 26.32 Ottlet | Ф | | 0 |
| 26.3 | For category (26.26) provide the following: | 2 | | 3 | _ |
| | Nature of Restriction | Description | | nount | |
| 27.1 | | | | 1 No | [X] |
| | Does the reporting entity have any hedging transactions report | ed on Schedule DB? | Yes [| - | 'A [X] |
| 27.2 | | red on Schedule DB? | | | |
| | If yes, has a comprehensive description of the hedging program | m been made available to the domiciliary state? Yes [| | | |
| | If yes, has a comprehensive description of the hedging program If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTIT | m been made available to the domiciliary state? Yes [| [] No | | [] |
| INES 2 | If yes, has a comprehensive description of the hedging program If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITY Does the reporting entity utilize derivatives to hedge variable at If the response to 27.3 is YES, does the reporting entity utilize: | m been made available to the domiciliary state? | Yes [Yes [Yes [Yes [|] No | [] [] |
| .INES 2 27.3 | If yes, has a comprehensive description of the hedging program if no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITY Does the reporting entity utilize derivatives to hedge variable at lift the response to 27.3 is YES, does the reporting entity utilize: 2 2 3 By responding YES to 27.41 regarding utilizing the special accordiolowing: • The reporting entity has obtained explicit approval from the Hedging strategy subject to the special accounting processors. • Actuarial certification has been obtained which indicate reserves and provides the impact of the hedging strate. • Financial Officer Certification has been obtained which | m been made available to the domiciliary state? | Yes [Yes [Yes [Yes [Yes [|] No | [] [] |
| 27.3 27.4 | If yes, has a comprehensive description of the hedging program if no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITY Does the reporting entity utilize derivatives to hedge variable at lift the response to 27.3 is YES, does the reporting entity utilize: 2 2 3 3 3 3 4 3 By responding YES to 27.41 regarding utilizing the special accordiolowing: • The reporting entity has obtained explicit approval from the deging strategy subject to the special accounting profuse Actuarial certification has been obtained which indicate reserves and provides the impact of the hedging strate Financial Officer Certification has been obtained which Hedging Strategy within VM-21 and that the Clearly Doi its actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 31 | m been made available to the domiciliary state? Yes [FIES ONLY: nnuity guarantees subject to fluctuations as a result of interest rate sensitivity? 17.41 Special accounting provision of SSAP No. 108 17.42 Permitted accounting practice 17.43 Other accounting guidance 17.43 Other accounting guidance 18. The domiciliary state of the domiciliary state of the matter domiciliary state ovisions is consistent with the requirements of VM-21. 18. The domiciliary state of VM-21 | Yes [|] No | |
| 27.3 27.4 27.5 | If yes, has a comprehensive description of the hedging program If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITY Does the reporting entity utilize derivatives to hedge variable at the response to 27.3 is YES, does the reporting entity utilize: 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 | m been made available to the domiciliary state? FIES ONLY: Innuity guarantees subject to fluctuations as a result of interest rate sensitivity? FIES ONLY: The state of interest rate sensitivity? T | Yes [|] No] No] No] No] | [X] |
| 27.3 27.4 27.5 28.1 | If yes, has a comprehensive description of the hedging program If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITY Does the reporting entity utilize derivatives to hedge variable at If the response to 27.3 is YES, does the reporting entity utilize: 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 | TIES ONLY: nnuity guarantees subject to fluctuations as a result of interest rate sensitivity? 17.41 Special accounting provision of SSAP No. 108 17.42 Permitted accounting practice 17.43 Other accounting guidance 17.40 Other accounting guidance 17.41 Special accounting practice 17.42 Permitted accounting practice 17.43 Other accounting guidance 18. Sound of SSAP No. 108, the reporting entity attests to the mathematical state of the sensitivity of the state of | Yes [|] No] No] No] No] | [] [] [] |
| 27.3 27.4 27.5 28.1 28.2 29. | If yes, has a comprehensive description of the hedging program If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITY Does the reporting entity utilize derivatives to hedge variable at the response to 27.3 is YES, does the reporting entity utilize: 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 | TIES ONLY: nnuity guarantees subject to fluctuations as a result of interest rate sensitivity? 17.41 Special accounting provision of SSAP No. 108 17.42 Permitted accounting practice 17.43 Other accounting guidance 17.40 Other accounting guidance 18.40 Other accounting guidance 19.41 Special accounting guidance 19.42 Permitted accounting guidance 19.43 Other accounting guidance 19.44 Other accounting guidance 19.44 Other accounting guidance 19.45 Other accounting guidance 19.46 Other accounting guidance 19.47 Other accounting guidance 10.48 Other accounting guidance 10.49 Other accounting guidance 10.40 | Yes [|] No] No] No] No] No | [] [] [] |
| 27.3 27.4 27.5 28.1 28.2 29. | If yes, has a comprehensive description of the hedging program If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITY Does the reporting entity utilize derivatives to hedge variable at the response to 27.3 is YES, does the reporting entity utilize: 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 | TIES ONLY: nnuity guarantees subject to fluctuations as a result of interest rate sensitivity? 7.41 Special accounting provision of SSAP No. 108 7.42 Permitted accounting practice 7.43 Other accounting guidance 7.43 Other accounting guidance 7.44 Special accounting guidance 7.45 Other accounting guidance 7.46 Other accounting guidance 7.47 Other accounting guidance 7.48 Other accounting guidance 7.49 Other accounting guidance 7.40 Other accounting guidance 7.40 Other accounting guidance 7.41 Special accounting guidance 7.42 Permitted accounting provision of SSAP No. 108 7.45 Other accounting guidance 7.46 Other accounting guidance 7.47 Other accounting guidance 7.48 Other accounting guidance 7.49 Other accounting guidance 7.40 Other accounting guidance 7.41 Special accounting provision of SSAP No. 108 7.42 Permitted accounting provision of SSAP No. 108 7.43 Other accounting guidance 7.44 Other accounting guidance 7.45 Other accounting guidance 7.46 Other accounting guidance 7.47 Other accounting guidance 7.48 Other accounting guidance 7.49 Other accounting guidance 7.49 Other accounting guidance 7.40 Other accounting guidance 7.40 Other accounting guidance 7.41 Other accounting guidance 7.42 Permitted accounting guidance 7.43 Other accounting guidance 7.44 Other accounting guidance 8.40 Other accounting guidance 8.41 Other accounting guidance 9.42 Other accounting guidance 9.43 Other accounting guidance 9.44 Other accounting guidance 9.45 Other accounting guidance 9.45 Other accounting guidance 9.46 Other accounting guidance 9.47 Other accounting guidance 9.48 Other accounting guidance 9.49 Other accounting guidance 9.40 Other accounting guidance 9 | Yes [|] No] No] No] No] No | [] [] [] |
| 27.3 27.4 27.5 28.1 28.2 29. | If yes, has a comprehensive description of the hedging program If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITY Does the reporting entity utilize derivatives to hedge variable at If the response to 27.3 is YES, does the reporting entity utilize: 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 | TIES ONLY: nnuity guarantees subject to fluctuations as a result of interest rate sensitivity? 17.41 Special accounting provision of SSAP No. 108 17.42 Permitted accounting practice 17.43 Other accounting guidance 17.43 Other accounting guidance 17.45 consistent with the requirements of VM-21. 18. Ites that the hedging strategy is incorporated within the establishment of VM-21 easy within the Actuarial Guideline Conditional Tail Expectation Amount. In indicates that the hedging strategy meets the definition of a Clearly Defined efined Hedging Strategy is the hedging strategy being used by the company in 1 of the current year mandatorily convertible into equity, or, at the option of the year. 1 estate, mortgage loans and investments held physically in the reporting entity's and other securities, owned throughout the current year held pursuant to a accordance with Section 1, III - General Examination Considerations, F. greements of the NAIC Financial Condition Examiners Handbook? | Yes [Yes [Yes [Yes [Yes [Yes [Yes [Yes [Yes [Yes [|] No No No No No No No No | [] [X] [X] |

| | 1 Name(s) | | 2 Location(s) | | 3 Complete Explana | . , | |
|---|---|---|--|--|---|-------------------------------|--|
| Have there been any | | changes, in the cust | todian(s) identified in | | year? | | |
| | 1 Custodian | | 2 Custodian | 3 Date of Change | | | |
| make investment dec | | orting entity. For ass | sets that are manage | | duals that have the authority to the reporting entity, note a | | |
| | 1 | | 2 | | | | |
| BI VCKBUCK EINVNUTVI | Name of Firm or Indiv | | Affilia | | | | |
| | WANAGEWENT, TNO | | | | | | |
| | | | | | | | |
| 29.0597 For those firr | ns/individuals listed in the | table for Question 2 | 29.05, do any firms/in | dividuals unaffiliated with | the reporting entity (i.e. | | |
| designated w | vith a "U") manage more th | nan 10% of the repo | rting entity's invested | assets? | | Yes [X |] No |
| total assets ι | 0 00 0 | gate to more than 50 | 0% of the reporting e | ntity's invested assets? | | _ |] No |
| the table below. | ividuals listed in the table f | or 29.05 with an am | illation code of "A" (a | miliated) or "O" (unamiliate | ed), provide the information fo | Г | |
| | | | | | | | |
| 1 | | 2 | | 3 | 4 | | 5 |
| 1 | | 2 | | 3 | 4 | I . | vestm |
| 1 Central Registration | | 2 | | 3 | 4 | Mai | vestmen nagen |
| Central Registration Depository Number | Name | of Firm or Individua | al la | Legal Entity Identifier (L | .EI) Registered With | Mai Ag (IN | vestmenagen greeme MA) Fil |
| Central Registration | | of Firm or Individua | al | | .EI) Registered With | Mai Ag (IN | vestmenagen greeme MA) Fil |
| Central Registration Depository Number 107105 Does the reporting en | Name BLACKROCK FINANCIAL MAN titty have any diversified mean (SEC) in the Investment | of Firm or Individua AGEMENT, INC | d in Schedule D, Part | Legal Entity Identifier (L 549300LVXY1VJKE13M84 | .EI) Registered With | Mai Ag (IN DS. | vestmenagem greemen MA) Fil |
| Central Registration Depository Number 107105 Does the reporting en Exchange Commission | Name BLACKROCK FINANCIAL MAN titty have any diversified mean (SEC) in the Investment | of Firm or Individua AGEMENT, INC | d in Schedule D, Part | Legal Entity Identifier (L 549300LVXY1VJKE13M84 | Registered With The SEC | Mai Aç (IN DS | vestmenagen greemena) Fil |
| Central Registration Depository Number 107105 Does the reporting en Exchange Commissic If yes, complete the fo | Name BLACKROCK FINANCIAL MAN titty have any diversified mean (SEC) in the Investment | of Firm or Individua AGEMENT, INC | d in Schedule D, Part | Legal Entity Identifier (L 549300LVXYIVJKE13M84 | Registered With The SEC | Mai Aç (IN) | vestmenagem nagem greemen MA) Fil |
| Central Registration Depository Number 107105 Does the reporting en Exchange Commissic If yes, complete the fo | Name BLACKROCK FINANCIAL MAN titty have any diversified mean (SEC) in the Investment | of Firm or Individua AGEMENT, INC | d in Schedule D, Part 940 [Section 5(b)(1)]) 2 | Legal Entity Identifier (L 549300LVXYIVJKE13M84 | Registered With The SEC | Mai Ag | vestmenagem nagem greemen MA) Fil |
| Central Registration Depository Number 107105 Does the reporting en Exchange Commissic If yes, complete the fo | Name BLACKROCK FINANCIAL MAN titty have any diversified mean (SEC) in the Investment | of Firm or Individua AGEMENT, INC utual funds reported t Company Act of 19 | d in Schedule D, Part 940 [Section 5(b)(1)]) 2 Name of Mutual F | Legal Entity Identifier (L 549300LVXYIVJKE13M84 | Registered With The SEC | Mai Ag | vestmenagen greemenA) Fil No sted alue |
| Central Registration Depository Number 107105 Does the reporting en Exchange Commissic If yes, complete the fo | Name BLACKROCK FINANCIAL MANu- attity have any diversified manual (SEC) in the Investment ollowing schedule: | of Firm or Individua AGEMENT, INC utual funds reported t Company Act of 19 | d in Schedule D, Part 940 [Section 5(b)(1)]) 2 Name of Mutual F | Legal Entity Identifier (L 549300LVXYIVJKE13M84 | Registered With The SEC | Yes [Book/Adjus Carrying Vs | vestmenagen greemenA) Fil No sted alue |

GENERAL INTERROGATORIES

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

| | 1 | 2 | 3 |
|-----------------------|----------------------|---------------|-------------------------|
| | | | Excess of Statement |
| | | | over Fair Value (-), or |
| | Statement (Admitted) | | Fair Value over |
| | Value | Fair Value | Statement (+) |
| 31.1 Bonds | 1,330,903,297 | 1,331,598,267 | 694,970 |
| 31.2 Preferred stocks | 0 | 0 | 0 |
| 31.3 Totals | 1,330,903,297 | 1,331,598,267 | 694,970 |

| 31.4 | Describe the sources or methods utilized in determining the fair values: Fair value of actively traded debt and equity securities are based on quoted market prices. Fair value of inactively traded debt securities are | | | | |
|--------------|--|-----|-------|---|----------|
| | based on quoted market prices of identical or similar securities or based on observable inputs like interest rates using either a market or income valuation. | | | | |
| 32.1 | Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D? | Yes | ; [|] | No [X] |
| 32.2 | If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source? | Yes | ; [|] | No [] |
| 32.3 | If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D: | | | | |
| 33.1 33.2 | Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed? | Yes | ; [X |] | No [] |
| 34. | By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security: a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available. b. Issuer or obligor is current on all contracted interest and principal payments. | | | | |
| | c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal. | | | | |
| | Has the reporting entity self-designated 5GI securities? | Yes | . [|] | No [X] |
| 35. | By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security: a. The security was purchased prior to January 1, 2018. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators. d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO. | | | | |
| | Has the reporting entity self-designated PLGI securities? | Yes |] ; | 1 | No [X] |
| 36. | By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund: a. The shares were purchased prior to January 1, 2019. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019. d. The fund only or predominantly holds bonds in its portfolio. | | • | | |
| | e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO. f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed. Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria? | Vor | 1 | 1 | No [X] |
| | | 168 | · L | 1 | NO [X] |
| 37. | By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following: a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date. b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties. c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for | | | | |
| | which documentation is available for regulator review. d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a - | | | | |
| | 37.c are reported as long-term investments. Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria? |] [| No [|] | N/A [X |

GENERAL INTERROGATORIES

OTHER

| 38.1 | Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any? | | \$ | 0 |
|------|---|--------------------------|--------------|---------|
| 38.2 | List the name of the organization and the amount paid if any such payment represented 25% or more of the to service organizations and statistical or rating bureaus during the period covered by this statement. | otal payments to trade a | ssociations, | |
| | 1 Name | 2 Amount Paid | | |
| 39.1 | Amount of payments for legal expenses, if any? | | \$ | .32,576 |
| 39.2 | List the name of the firm and the amount paid if any such payment represented 25% or more of the total paymenting the period covered by this statement. | ents for legal expenses | 3 | |
| | 1 Name | 2 | | |
| | Name | Amount Paid | | |
| | SANDS ANDERSON PC | 8,750 | | |
| | FOX ROTHSCHILD LLP | 8,315 | | |
| | | | | |
| 40.1 | Amount of payments for expenditures in connection with matters before legislative bodies, officers or department | ents of government, if a | any?\$ | 0 |
| 40.2 | List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment connection with matters before legislative bodies, officers or departments of government during the period cov | | | |
| | 1 | 2 | | |
| | Name | Amount Paid | | |

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

| 1.1 | Does the reporting entity have any direct Medicare Supplement Insurance in for | | | - | | ^ |
|------------|--|---|---------|--------|-------|--------------|
| 1.2 1.3 | If yes, indicate premium earned on U.S. business only | oo Evnorianaa Evhihit? | > | | | 0 |
| 1.5 | 1.31 Reason for excluding | e Experience Exhibit: | .Ψ | | | - |
| | | | | | | |
| | | | | | | |
| 1.4 | Indicate amount of earned premium attributable to Canadian and/or Other Alien | not included in Item (1.2) above | \$ | | | 0 |
| 1.5 | Indicate total incurred claims on all Medicare Supplement Insurance. | | \$ | | | 0 |
| 1.6 | Individual policies: | Most current three years: | | | | |
| | | 1.61 Total premium earned | .\$ | | | 0 |
| | | 1.62 Total incurred claims | | | | |
| | | 1.63 Number of covered lives | | | | 0 |
| | | All years prior to most current three years: 1.64 Total premium earned | • | | | ٥ |
| | | 1.65 Total incurred claims | | | | ٥٥ |
| | | 1.66 Number of covered lives | | | | |
| | | 1.00 Number of Governou investigation | | | | • |
| 1.7 | Group policies: | Most current three years: | | | | |
| | | 1.71 Total premium earned | \$ | | | 0 |
| | | 1.72 Total incurred claims | | | | |
| | | 1.73 Number of covered lives | | | | 0 |
| | | All years prior to most current three years: | | | | |
| | | 1.74 Total premium earned | | | | |
| | | 1.75 Total incurred claims | | | | |
| | | 1.76 Number of covered lives | | | | 0 |
| • | Hardin Tarak | | | | | |
| 2. | Health Test: | 1 2 | | | | |
| | | Current Year Prior Year | | | | |
| | 2.1 Premium Numerator | | | | | |
| | 2.2 Premium Denominator | | | | | |
| | 2.3 Premium Ratio (2.1/2.2) | 1.0001.000 | | | | |
| | 2.4 Reserve Numerator | 671,426,767 | | | | |
| | 2.5 Reserve Denominator | | | | | |
| | 2.6 Reserve Ratio (2.4/2.5) | 1.0001.000 | | | | |
| 3.2 | returned when, as and if the earnings of the reporting entity permits? | | Yes [|] No | [X] | |
| 4.1 | Have copies of all agreements stating the period and nature of hospitals', physic | | | | | |
| | dependents been filed with the appropriate regulatory agency? | | Yes [X | (] No | [] | |
| 4.2 | If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do the | se agreements include additional benefits offered? | Yes [|] No | [X] | |
| 5.1 | Does the reporting entity have stop-loss reinsurance? | | Yes [|] No | [X] | |
| 5.2 | If no, explain: Stop-Loss Reinsurance is not required | | | | | |
| | Stop 2000 Nemourance to not required | | | | | |
| 5.3 | Maximum retained risk (see instructions) | 5.31 Comprehensive Medical | | | | |
| | | 5.32 Medical Only | | | | |
| | | 5.33 Medicare Supplement | | | | |
| | | 5.34 Dental & Vision | | | | |
| | | 5.35 Other Limited Benefit Plan5.36 Other | | | | |
| 6. | Describe arrangement which the reporting entity may have to protect subscriber hold harmless provisions, conversion privileges with other carriers, agreements agreements: | rs and their dependents against the risk of insolvency including with providers to continue rendering services, and any other | .sp | | | 0 |
| | Provider contracts include hold harmless and continuation of benefits provisions company. | | | | | |
| 7.1 | Does the reporting entity set up its claim liability for provider services on a service | ce date basis? | Yes [X | [] No | [] | |
| 7.2 | If no, give details | | | | | |
| 8. | Provide the following information regarding participating providers: | 8.1 Number of providers at start of reporting year . 8.2 Number of providers at end of reporting year | | | | |
| 9.1 | Does the reporting entity have business subject to premium rate guarantees? | , , , | | | | |
| | · · · · · · · · · · · · · · · · · · · | | | | | |
| 9.2 | If yes, direct premium earned: | 9.21 Business with rate guarantees between 15-36 months. 9.22 Business with rate guarantees over 36 months | | | | |

GENERAL INTERROGATORIES

| 10.1 | Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its | s provider contracts? | Yes [| Х] | No | [|] |
|--------------------------------------|--|--------------------------------------|---------------------------|-----|-----------|-------------------------|--------------|
| 10.2 | | 10.21 Maximum amount payable bonuses | \$ \$ | | 75 | ,653, | , 190 0 |
| 11.1 | Is the reporting entity organized as: | 11.12 A Medical Group/Staff Model, | Yes [Yes [Yes [| - 1 | No | X] c X] c X] c | i |
| 11.2 11.3 11.4 11.5 11.6 | Is the reporting entity subject to Statutory Minimum Capital and Surplus Requirement If yes, show the name of the state requiring such minimum capital and surplus | | Yes [.\$ Yes [| | Wa 796 | shing 5,018, | gton ,010 |

12. List service areas in which reporting entity is licensed to operate:

| 1 Name of Service Area |
|---|
| AL - Medicare - Autauga, Baldwin, Bibb, Cherokee, Clarke, Colbert, Cullman, Elmore, Escambia, Etowah, Fayette, Jackson, Jefferson, |
| Lauderdale, Lawrence, Limestone, Madison, Marshall, Mobile, Monroe, Montgomery, Morgan, Pike, Shelby, Tuscaloosa, Walker, Washington |
| AK - Medicare - Anchorage, Fairbanks, North Star, Ketchikan Gateway, Juneau, Matanuska-Susitna |
| AZ - Medicare - Coconino, Mohave, Yavapai |
| AR - Medicare - Arkansas, Baxter, Benton, Boone, Carroll, Clark, Cleburne, Conway, Craighead, Crawford, Crittenden, Faulkner, Franklin, Fulton, Garland, Grant, Greene, Hempstead, Hot Spring, Howard, Independence, Izard, Jefferson, Johnson, Lawrence, Little River, Logan, Lonoke, Madison, Marion, Miller, Nevada, Newton, Ouachita, Perry, Pike, Poinsett, Polk, Pope, Prairie, Pulaski, Randolph, Saline, Scott, Searcy, Sebastian, Sevier, Sharp, Union, Van Buren, Washington, White |
| Kings, Lake, Los Angeles, Madera, Marin, Mendocino, Merced, Monterey, Orange, Placer, Riverside, Sacramento, San Bernardino, San Diego, San Francisco, San Joaquin, San Luis Obispo, San Mateo, Santa Barbara, Santa Clara, Santa Cruz, Shasta, Solano, Sonoma, Stanislaus, Tehama, Tulare, Tuolumne, Ventura, Yolo |
| ID - Medicare - Ada, Bonner, Canyon, Kootenai, Payette |
| IN - Medicare - Adams, Allen, Boone, Cass, Clark, De Kalb, Delaware, Elkhart, Floyd, Gibson, Grant, Hamilton, Hancock, Hendricks, Henry, Howard, Huntington, Jasper, Johnson, Kosciusko, Lake, La Grange, La Porte, Lawrence, Lake, Madison, Marion, Marshall, Miami, Monroe, Montgomery, Morgan, Noble, Porter, Posey, St. Joseph, Tippecanoe, |
| Vanderburgh, Wabash, Warrick, Wells, Whitley |
| KY - Medicare - Statewide |
| MO - Medicare - Barry, Cedar, Christian, Dade, Dallas, Douglas, Greene, |
| Jasper, Laclede, Lawrence, McDonald, Newton, Polk, Pulaski, Stone, Taney, Webster, Wright |
| NE - Medicare - Cass, Dakota, Dodge, Douglas, Lancaster, Sarpy, |
| Saunders, Washington NH - Medicare - Belknap, Carroll, Hillsborough, Merrimack, Rockingham, Strafford |
| OK - Medicare - Le Flore, Sequoyah |
| SC - Medicare - Allendale, Anderson, Berkeley, Charleston, Cherokee, Colleton, Dorchester, Greenville, Pickens, Richland, Spartanburg, York TX - Medicare - Statewide |
| VA - Medicare - Botetourt, Chesapeake City, Franklin, Norfolk City, |
| Portsmouth City, Roanoke, Roanoke City, Salem City, Virginia Beach City, Albemarle, Alexandria City, Arlington, Charlottesville City, |
| Chesterfield, Colonial Heights City, Craig, Dinwiddie, Falls Church City, Fauquier, Floyd, Goochland, Hampton City, Hanover, Henrico, Hopewell City, Isle of Wight, James City, Loudoun, Louisa, Manassas City, |
| Manassas Park City, Montgomery, Newport News City, Petersburg City, Poquoson City, Powhatan, Prince William, Pulaski, Radford City, Richmond |
| City, Suffolk City, Williamsburg City, Wythe, York, Accomack, Alleghany, Amelia, Amherst, Appomattox, Augusta, Bath, Bedford, Bedford City, Bland, Brunswick, Buckingham, Buena Vista City, Campbell, Caroline, |
| Carroll, Charles City, Charlotte, Clarke, Covington City, Culpeper, Cumberland, Danville City, Emporia City, Essex, Fairfax, Fairfax City, |
| Frederick, Fredericksburg City, Galax City, Giles, Gloucester, Greene, Greenville, Halifax, Harrisonburg City, Henry, King and Queen, King George, King William, Lancaster, Lexington City, Lunenburg, Lynchburg |
| City, Madison, Martinsville City, Mathews, Mecklenburg, Lynchold Nelson, New Kent, Northampton, Northumberland, Nottoway, Orange, Page, Patrick, Pittsylvania, Prince Edward, Prince George, Rappahannock, |
| Richmond, Rockbridge, Rockingham, Shenandoah, Southampton, Spotsylvania, Stafford, Staunton City, Surry, Sussex, Warren, Waynesboro |
| City, Westmoreland, Winchester City, Highland, Franklin City, Fluvanna . WA - Medicare - Statewide |

| Name of Service Area | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|
| WV - Medicare - Boone, Cabell, Kanawha, Lincoln, McDowell, Mercer, | | | | | | | | | |
| Monroe, Putnam, Barbour, Berkeley, Braxton, Brooke, Calhoun, Clay, | | | | | | | | | |
| Doddridge, Fayette, Gilmer, Grant, Greenbrier, Hampshire, Hancock, Hardy | | | | | | | | | |
| Harrison, Jackson, Jefferson, Lewis, Logan, Marion, Marshall, Mason, | | | | | | | | | |
| Mineral, Mingo, Monongalia, Morgan, Nicholas, Ohio, Pendleton, | | | | | | | | | |
| Pleasants, Pocahontas, Preston, Raleigh, Randolph, Ritchie, Roane, | | | | | | | | | |
| Summers, Taylor, Tucker, Tyler, Upshur, Wayne, Webster, Wetzel, Wirt, | | | | | | | | | |
| Wood, Wyoming | | | | | | | | | |
| | | | | | | | | | |

13.1 Do you act as a custodian for health savings accounts? Yes [] No [X]

| 13.2 | 13.2 If yes, please provide the amount of custodial funds held as of the reporting date. | | | | | | | | 0 |
|--|---|---------------------------------------|-----------------------------|-------------------|---------------------------|--------------------------|------------|------|----------|
| 13.3 | 3.3 Do you act as an administrator for health savings accounts? | | | | | | | | [X] |
| 13.4 | 3.4 If yes, please provide the balance of funds administered as of the reporting date. | | | | | | | | |
| 14.1 14.2 | 100 [] 100 [| | | | | | | | /A [X] |
| | 1 | 2 | 3 | 4 | Assets | Supporting Reserv | ve Credit | | 1 |
| | Company Name | NAIC Company Code | Domiciliary Jurisdiction | Reserve Credit | 5 Letters of Credit | 6 Trust Agreements | 7 Other | | |
| | Company Name | Occ | dansaiction | Orcan | Credit | Agreements | Other | | 1 |
| 15. | Provide the following for individual ordinary life insu ceded): | ance assumed or ittenns I Lives | \$ | | 0 | | | | |
| | *Ondings. Life Incompany Includes | | | | | | | | |
| | *Ordinary Life Insurance Includes Term(whether full underwriting, limited underwriting, jet issue, "short form app") | | | | | | | | |
| | Whole Life (whether full underwriting, limited underwriting, jet issue, "short form app") | | | | | | | | |
| | Variable Life (with or without secondary gurarantee) | | | | | | | | |
| | Universal Life (with or without secondary gurarantee) Variable Universal Life (with or without secondary gurarantee) | | | | | | | | |
| 16. | S. Is the reporting entity licensed or chartered, registered, qualified, eligible or writing business in at least two states? | | | | | | |] | |
| 16.1 If no, does the reporting entity assume reinsurance business that covers risks residing in at least one state other than the state of domicile of the reporting entity? | | | | | | | | No [|] |

FIVE-YEAR HISTORICAL DATA

| | | 1 2021 | 2 2020 | 3 2019 | 4 2018 | 5 2017 |
|-----|--|---|-------------------------------------|---|---|-------------|
| | Balance Sheet (Pages 2 and 3) | 2021 | 2020 | 2010 | 2010 | 2017 |
| 1. | Total admitted assets (Page 2, Line 28) | 1 751 171 135 | 1 596 487 759 | 1,246,852,729 | 834,259,468 | 305,860,486 |
| 2. | Total liabilities (Page 3, Line 24) | | | | 322,774,745 | 68,333,037 |
| 3. | Statutory minimum capital and surplus requirement . | | | | 427,209,750 | 100,446,839 |
| 4. | Total capital and surplus (Page 3, Line 33) | | | | 511,484,723 | 237,527,449 |
| ٦. | Income Statement (Page 4) | 312,020,107 | 970,010,220 | 10,700,100 | 311, 101,720 | 207,027,110 |
| 5. | Total revenues (Line 8) | 6 368 144 084 | 5 513 801 635 | 4 345 827 532 | 3 417 678 000 | 803 574 710 |
| 6. | Total medical and hospital expenses (Line 18) | | | | 2,873,947,669 | |
| 7. | Claims adjustment expenses (Line 20) | | | | 101,885,116 | |
| 8. | Total administrative expenses (Line 21) | | | | 365, 138, 130 | 78,617,150 |
| 9. | Net underwriting gain (loss) (Line 24) | | | | | |
| 10. | Net investment gain (loss) (Line 27) | | | | 17,518,789 | |
| 11. | Total other income (Lines 28 plus 29) | | | | 94 | |
| 12. | Net income or (loss) (Line 32) | | | | 59,729,263 | |
| 12. | Cash Flow (Page 6) | | | | 90,720,200 | 20,000,020 |
| 13. | Net cash from operations (Line 11) | 135 960 515 | 242 554 123 | 283 368 857 | 207 595 571 | (2 790 557 |
| 10. | Risk-Based Capital Analysis | | | 200,000,001 | | (2,700,007 |
| 14. | Total adjusted capital | 912 923 407 | 879 045 229 | 716 768 438 | 511 484 723 | 237 527 449 |
| 15. | Authorized control level risk-based capital | | | | | |
| | Enrollment (Exhibit 1) | | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | | | |
| 16. | Total members at end of period (Column 5, Line 7) | 491.705 | 445.510 | 385.108 | 323.381 | 79.533 |
| 17. | Total members months (Column 6, Line 7) | | | | 3,792,467 | 932.334 |
| | Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0 | , | | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | ,,,, |
| 18. | Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5) | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| 19. | Total hospital and medical plus other non-health (Lines 18 plus Line 19) | 85.9 | 83.0 | 84.5 | 84.1 | 87.4 |
| 20. | Cost containment expenses | 2.8 | 2.6 | 2.8 | 2.5 | 2.0 |
| 21. | Other claims adjustment expenses | | | | | |
| 22. | Total underwriting deductions (Line 23) | | | | | |
| 23. | Total underwriting gain (loss) (Line 24) | 2.3 | 3.0 | 3.2 | 2.2 | 3.1 |
| | Unpaid Claims Analysis (U&I Exhibit, Part 2B) | | | | | |
| 24. | Total claims incurred for prior years (Line 13, Col. 5) | 482,245,079 | 363,574,992 | 222,912,075 | 41,616,444 | 57,916,286 |
| 25. | Estimated liability of unpaid claims-[prior year (Line 13, Col. 6)] | 561,854,363 | 361,247,174 | 235,169,737 | 37,628,163 | 68,265,438 |
| | Investments In Parent, Subsidiaries and Affiliates | | | | | |
| 26. | Affiliated bonds (Sch. D Summary, Line 12, Col. 1) | 0 | 0 | 0 | 0 | 0 |
| 27. | Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1) | 0 | 0 | 0 | 0 | 0 |
| 28. | Affiliated common stocks (Sch. D Summary, Line 24, Col. 1) | 0 | 0 | 0 | 0 | 0 |
| 29. | Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10) | 0 | 0 | 0 | 0 | 0 |
| 30. | Affiliated mortgage loans on real estate | | | | | 1 |
| 31. | All other affiliated | | | | | 1 |
| 32. | Total of above Lines 26 to 31 | | | | | 1 |
| 33. | Total investment in parent included in Lines 26 to 31 above. | 0 | 0 | 0 | | 0 |
| | | • | · | compliance with the di | · · | 1 |

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories


| | | | 1 | 1 | | | | | | | | |
|------------------|---|----------|-------------------------|------------------------------------|-------------------------|-----------------------|-------------------|--|---|-----------------------------------|---------------------------------|---------------------------|
| | | | | 2 | 3 | 4 | 5 | rect Business O 6 Federal Employees | 7 Life and | 8 | 9 | 10 |
| | States, etc. | | Active Status (a) | Accident and Health Premiums | Medicare Title XVIII | Medicaid Title XIX | CHIP Title XXI | Health Benefits Program Premiums | Annuity Premiums & Other Considerations | Property/ Casualty Premiums | Total Columns 2 Through 8 | Deposit-Type Contracts |
| | | AL | L | 0 | 629,484,372 | 0 | 0 | 0 | 0 | 0 | 629,484,372 | 0 |
| | | AK AZ | L | 0 | 0 | 0 | 0 0 | 0 | 0 0 | 0 | 0 | 0 |
| | | AZ AR | L | 0 | 517,044,854 | 0 | 0 | 0 | 0 | 0 | 517,044,854 | 0 |
| | | CA | | 0 | 1,325,538,003 | 0 | 0 | 0 | 0 | 0 | 1,325,538,003 | 0 |
| | | CO | L | 0 | 0 | 0 | 0 | o | 0 | 0 | 1,323,336,003 | o |
| | | CT | N | 0 | 0 | 0 | 0 | n | 0 | 0 | 0 | o |
| | | DE | N | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | 0 |
| | District of Columbia | I | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | FL | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | GA | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | • | HI | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 13. | Idaho | ID . | L | 0 | 19,521,645 | 0 | 0 | 0 | 0 | 0 | 19,521,645 | 0 |
| 14. | Illinois | IL . | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 15. | Indiana | IN . | L | 0 | 1,037,992,000 | 0 | 0 | 0 | 0 | 0 | 1,037,992,000 | 0 |
| 16. | lowa | IA . | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | KS | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | • | KY | L | 0 | 412,705,060 | 0 | 0 | 0 | 0 | 0 | 412,705,060 | 0 |
| | | LA | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | ME | L | 0 | 100,018,353 | 0 | 0 | 0 | 0 | 0 | 100,018,353 | 0 |
| | = | MD | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | MA | N. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | • | MI | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ļ0 | 0 |
| | | MN | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ļ0 |
| | | MS | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | MO | L | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | MT | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | NE | N N | 0 | (618) | 0 | 0 | 0 | 0 | 0 | (618) | 0 |
| | | NV | N I | 0 | 0 | 0 | 0 0 | 0 | 0 | 0 | 0 | 0 |
| | New Hampshire New Jersey | NH | L N | 0 | 34, 133, 650 | 0 0 | 0 | 0 | 0 0 | 0 | 34, 133, 650 | ۰ |
| | = | NM . | N N | 0 | 0 | 0 | 0 | ر | 0 | 0 | | ر م |
| | | NY | N N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | n |
| | North Carolina | I | N N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | n | n |
| | | ND I | NN | 0 | 0 | 0 | 0 | n | 0 | 0 | 0 | n |
| | | OH | N. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | n |
| | | ok | | 0 | 10,704 | 0 | 0 | n | 0 | 0 | 10,704 | n |
| | | OR | N. | 0 | 0,704 | 0 | 0 | 0 | 0 | 0 | n | 0 |
| | • | PA | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | - | RI | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | South Carolina | | L | 0 | 1,108,251,533 | 0 | 0 | 0 | 0 | 0 | 1,108,251,533 | 0 |
| | | SD | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | TN | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 44. | Texas | TX | L | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 45. | Utah | UT | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Vermont | | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 47. | Virginia | VA | L | 0 | 452,224,937 | 0 | 0 | 0 | 0 | 0 | 452,224,937 | 0 |
| | | WA | L | 0 | 635,296,048 | 0 | 0 | 0 | 0 | 0 | 635,296,048 | 0 |
| | West Virginia | | L | 0 | 95,923,541 | 0 | 0 | 0 | 0 | 0 | 95,923,541 | 0 |
| | | WI | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Wyoming | | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ļ0 |
| | American Samoa | | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | GU | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Puerto Rico | | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | U.S. Virgin Islands | VI | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 56. | Northern Mariana Islands | MP | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | _ | |
| 57. | | CAN | N | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | n |
| | Aggregate Other | J/111 | | | [| | | | | 0 | | |
| J | Aliens | ОТ | XXX | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 59. | Subtotal | | XXX | 0 | 6,368,144,084 | 0 | 0 | 0 | 0 | 0 | 6,368,144,084 | 0 |
| 60. | Reporting Entity Contributions for Em | ployee | V/// | | | _ | _ | _ | | ^ | | _ |
| 64 | Benefit Plans | | XXX | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Totals (Direct Busines | | XXX | 0 | 6,368,144,084 | 0 | 0 | 0 | 0 | 0 | 6,368,144,084 | 0 |
| 58001. | DETAILS OF WRITE | -INS | V004 | | | ^ | 0 | 0 | 0 | 0 | _ | _ |
| 58001. 58002. | | | XXX | 0 | 0 | 0 | 0 | J0 | J0 | 0 | 0 | 0 |
| 58002. | | | XXX | | † | | | † | | | t | |
| | Summary of remainin | q | | | † | | · | † | | | † | · |
| | write-ins for Line 58 fr | | | | | | | | | | | |
| | overflow page | | XXX | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | Totals (Lines 58001 tl 58003 plus 58998)(Lines 58998) | | | | | | | | | | | |
| | DOUGLOUIS SKYYKI(LII | ne og | XXX | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |


| (a) | Active | Status | Counts: |
|-----|--------|--------|---------|


^{.....18}0

⁽b) Explanation of basis of allocation by states, premiums by state, etc. The Company reports premium based on the situs of the contract


R - Registered - Non-domiciled RRGs......0
Q - Qualified - Qualified or accredited reinsurer......0








40.2





Echo Primary Care Holdings Organization Chart





As of 12/31/2021


Prime West Management Organizational Chart
































































OVERFLOW PAGE FOR WRITE-INS

NONE